GeneDx (WGS) 10-Q 12 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	Apr. 29, 2022
Entity Listings [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-39482
Entity Registrant Name	Sema4 Holdings Corp.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-1966622
Entity Address, Address Line One	333 Ludlow Street
Entity Address, Address Line Two	North Tower, 8th Floor
Entity Address, City or Town	Stamford
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06902
City Area Code	800
Local Phone Number	298-6470
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		377,249,186
Entity Central Index Key	0001818331
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Class A common stock
Entity Listings [Line Items]
Title of 12(b) Security	Class A common stock, par value $0.0001 per share
Trading Symbol	SMFR
Security Exchange Name	NASDAQ
Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Entity Listings [Line Items]
Title of 12(b) Security	Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share
Trading Symbol	SMFRW
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 315,002	$ 400,569
Accounts receivable, net	37,642	26,509
Due from related parties	125	54
Inventory, net	36,318	33,456
Prepaid expenses	17,241	19,154
Other current assets	4,096	3,802
Total current assets	410,424	483,544
Operating lease assets	38,417	0
Property and equipment, net		62,719
Property and equipment, net	60,976
Restricted cash	900	900
Other assets	6,953	6,930
Total assets	517,670	554,093
Current liabilities:
Accounts payable and accrued expenses	68,880	64,801
Due to related parties	3,237	2,623
Contract liabilities	66	473
Short-term lease liabilities	5,072	0
Other current liabilities	23,384	33,387
Total current liabilities	100,639	101,284
Long-term debt, net of current portion	11,000	11,000
Long-term lease liabilities	57,478	0
Other liabilities	500	21,907
Warrant liability	15,177	21,555
Earn-out contingent liability	3,432	10,244
Total liabilities	188,226	165,990
Commitments and contingencies
Stockholders’ equity:
Preferred Stock, $0.0001 par value: 1,000,000 and 0 shares authorized at March 31, 2022 and December 31, 2021, respectively; 0 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively	0	0
Class A common stock, $0.0001 par value, 380,000,000 shares authorized, 245,154,475 shares issued and outstanding at March 31, 2022 and $0.0001 par value: 380,000,000 shares authorized, 242,647,604 shares issued and outstanding at December 31, 2021	24	24
Additional paid-in capital	981,757	963,520
Accumulated deficit	(652,337)	(575,441)
Total stockholders’ equity	329,444	388,103
Total liabilities and stockholders’ equity	$ 517,670	$ 554,093

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	1,000,000	0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	380,000,000	380,000,000
Common stock, issued (in shares)	245,154,475	242,647,604
Common stock, outstanding (in shares)	245,154,475	242,647,604

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total revenue	$ 53,941	$ 64,201	[1]
Cost of services (including related party expenses of $1,056 and $278 for the three months ended March 31, 2022 and 2021, respectively)	48,316	68,524	[1]
Gross profit (loss)	5,625	(4,323)	[1]
Research and development	21,315	53,133	[1]
Selling and marketing	29,547	35,366	[1]
General and administrative	42,784	102,038	[1]
Related party expenses	1,284	1,797	[1]
Loss from operations	(89,305)	(196,657)	[1]
Other income (expense), net:
Change in fair market value of warrant and earn-out contingent liabilities	13,190	0	[1]
Interest income	27	21	[1]
Interest expense	(808)	(723)	[1]
Other income	0	5,584	[1]
Total other income (expense), net	12,409	4,882	[1]
Loss before income taxes	(76,896)	(191,775)	[1]
Income tax provision	0	0	[1]
Net loss	(76,896)	(191,775)	[1],[2],[3]
Comprehensive income	$ (76,896)	$ (191,775)	[1]
Weighted average shares outstanding, basic (in shares)	244,368,743	549,778
Weighted average shares outstanding, diluted (in shares)	244,368,743	549,778
Basic net loss per share (in dollars per share)	$ (0.31)	$ (348.82)
Diluted net loss per share (in dollars per share)	$ (0.31)	$ (348.82)
Class A Common Stock
Other income (expense), net:
Weighted average shares outstanding, basic (in shares)	244,368,743	549,778	[1]
Weighted average shares outstanding, diluted (in shares)	244,368,743	549,778	[1]
Basic net loss per share (in dollars per share)	$ (0.31)	$ (348.82)	[1]
Diluted net loss per share (in dollars per share)	$ (0.31)	$ (348.82)	[1]
Diagnostic test revenue
Total revenue	$ 52,495	$ 62,760	[1]
Other revenue
Total revenue	$ 1,446	$ 1,441	[1]
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to reclassify certain expenses between cost of services and operating expenses. The adjustments are reflected as disclosed.
[2]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to certain current asset and liability accounts previously reported in the condensed balance sheets as of March 31, 2021. The adjustments are reflected accordingly as disclosed. T
[3]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made which impacted previously reported net loss for the first quarter of 2021 and the adjusted net loss is reflected as disclosed.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total revenue	$ 53,941	$ 64,201	[1]
Cost of services	48,316	68,524	[1]
Affiliated Entities
Cost of services	1,056	278
Diagnostic test revenue
Total revenue	52,495	62,760	[1]
Diagnostic test revenue | Affiliated Entities
Total revenue	170	33
Other revenue
Total revenue	1,446	1,441	[1]
Other revenue | Affiliated Entities
Total revenue	$ 74	$ 27
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to reclassify certain expenses between cost of services and operating expenses. The adjustments are reflected as disclosed.

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Redeemable Convertible Preferred Stock Stockholders' Equity (Deficit) - USD ($) $ in Thousands		Total		Preferred Stock	Additional paid-in capital	Accumulated deficit	Class A Common Stock	Class A Common StockCommon Stock	Class B Common StockCommon Stock
Beginning balance (in shares) at Dec. 31, 2020	[1]	171,535,213
Beginning balance at Dec. 31, 2020	[1]	$ 334,439
Ending balance (in shares) at Mar. 31, 2021	[1]	171,535,213
Ending balance at Mar. 31, 2021	[1]	$ 334,439
Beginning balance (in shares) at Dec. 31, 2020	[1]							124	130,557
Beginning balance at Dec. 31, 2020	[1]	(330,051)			$ 0	$ (330,051)		$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	[1]	(191,775)	[2],[3]			(191,775)
Common stock class B issued pursuant to stock options (in shares)	[1]								618,204
Common stock class B issued pursuant to stock options	[1]	0
Ending balance (in shares) at Mar. 31, 2021	[1]							124	748,761
Ending balance at Mar. 31, 2021	[1]	(521,826)			0	(521,826)		$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2021								242,647,604
Beginning balance at Dec. 31, 2021		388,103			963,520	(575,441)		$ 24
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss		(76,896)				(76,896)
Stock option exercises (in shares)							2,108,502	2,108,502
Stock option exercises		678			678
Stock based compensation expense		17,559			17,559
Vested restricted stock units converted to common stock (in shares)								398,369
Ending balance (in shares) at Mar. 31, 2022				0				245,154,475
Ending balance at Mar. 31, 2022		$ 329,444		$ 0	$ 981,757	$ (652,337)		$ 24
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made which impacted previously reported net loss for the first quarter of 2021 and the adjusted net loss is reflected as disclosed.
[2]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to certain current asset and liability accounts previously reported in the condensed balance sheets as of March 31, 2021. The adjustments are reflected accordingly as disclosed. T
[3]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to reclassify certain expenses between cost of services and operating expenses. The adjustments are reflected as disclosed.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net loss		$ (76,896)	$ (191,775)	[1],[2],[3]
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense		5,803	4,902	[1]
Stock-based compensation expense		17,559	164,962	[1]
Change in fair value of warrant and earn-out contingent liabilities		(13,190)	0	[1]
Provision for excess and obsolete inventory		43	1,821	[1]
Non-cash lease expense		167	191	[1]
Amortization of deferred debt issuance costs		128	0	[1]
Change in operating assets and liabilities:
Accounts receivable		(11,132)	(1,296)	[1]
Inventory		(2,904)	(9,828)	[1]
Prepaid expenses and other current assets		1,596	(6,327)	[1]
Due to/from related parties		543	(688)	[1]
Other assets		(151)	0	[1]
Accounts payable and accrued expenses		3,932	3,951	[1]
Contract liabilities		(408)	1,027	[1]
Other current liabilities		(6,584)	(9,148)	[1]
Net cash used in operating activities		(81,494)	(42,208)	[1]
Investing activities
Purchases of property and equipment		(1,378)	(2,075)	[1]
Development of internal-use software assets		(2,535)	(2,919)	[1]
Net cash used in investing activities		(3,913)	(4,994)	[1]
Financing activities
Payment of deferred transaction costs		0	(1,254)	[1]
Finance lease principal payments		(862)
Finance lease principal payments	[1]		(1,052)
Long-term debt principal payments		0	(394)	[1]
Exercise of stock options		702	422	[1]
Net cash used in financing activities		(160)	(2,278)	[1]
Net decrease in cash, cash equivalents and restricted cash		(85,567)	(49,480)	[1]
Cash, cash equivalents and restricted cash, at beginning of period		401,469	118,960	[1]
Cash, cash equivalents and restricted cash, at end of period		315,902	69,480	[1]
Supplemental disclosures of cash flow information
Cash paid for interest		607	723	[1]
Cash paid for taxes		168	0	[1]
Purchases of property and equipment in accounts payable and accrued expenses		1,325	1,164	[1]
Software development costs in accounts payable and accrued expenses		717	1,570	[1]
Unpaid deferred transaction costs included in accounts payable and accrued expenses		$ 227	$ 4,228	[1]
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to certain current asset and liability accounts previously reported in the condensed balance sheets as of March 31, 2021. The adjustments are reflected accordingly as disclosed. T
[2]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to reclassify certain expenses between cost of services and operating expenses. The adjustments are reflected as disclosed.
[3]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made which impacted previously reported net loss for the first quarter of 2021 and the adjusted net loss is reflected as disclosed.

Organization and Description of

Organization and Description of Business	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Sema4 Holdings Corp. (“Sema4 Holdings”) through its subsidiary Sema4 OpCo, Inc.,, formerly Mount Sinai Genomics Inc., a Delaware corporation (“Legacy Sema4”), as discussed further below, provides genomics-related diagnostic and information services and pursues genomics medical research. Legacy Sema4 utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. Legacy Sema4 provides a variety of genetic diagnostic tests and information with a focus on reproductive health, including pediatric, oncology and other conditions. Legacy Sema4 primarily serves healthcare professionals who work with their patients and bills third-party payors across the United States, with a substantial portion of its diagnostic testing volume occurring in New York, California, Florida, Connecticut and New Jersey. On July 22, 2021 (the “Closing Date”), CM Life Sciences, Inc. (“CMLS”) completed the acquisition of Legacy Sema4, pursuant to that certain Agreement and Plan of Merger (as amended, the “Prior Merger Agreement”), dated February 9, 2021. On the Closing Date, S-IV Sub, Inc. (“Prior Merger Sub”) merged with and into the Legacy Sema4, with Legacy Sema4 surviving the merger as a wholly-owned subsidiary of CMLS (the “Prior Merger” and, together with the other transactions contemplated by the Prior Merger Agreement, the “Business Combination”). In connection with the consummation of the Business Combination, CMLS changed its name to “Sema4 Holdings Corp.” and Legacy Sema4 changed its name to “Sema4 OpCo, Inc.” All equity securities of Legacy Sema4 were converted into the right to receive the applicable portion of the merger consideration. The Prior Merger was accounted for as a reverse recapitalization with Legacy Sema4 as the accounting acquirer and CMLS as the acquired company for accounting purposes. The shares and net loss per common share, prior to the Prior Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Prior Merger (1 share of Legacy Sema4 Class A common stock for 123.8339 shares of Sema4 Holdings Class A common stock (the “Class A common stock”)) (the “Conversion Ratio”). Prior to the Prior Merger, shares of CMLS Class A common stock, CMLS’s public warrants, and CMLS’s public units were traded on the Nasdaq Capital Market under the ticker symbols “CMLF”, “CMFLW”, and “CMLFU” respectively. On July 23, 2021, shares of Sema4 Holdings Class A common stock and Sema4 Holdings’ public warrants began trading on the Nasdaq Global Select Market (the “Nasdaq”) under the ticker symbols “SMFR” and “SMFRW,” respectively. See Note 3, “Business Combination,” for additional details. Unless otherwise stated herein or unless the context otherwise requires, references in these notes to the “Company,” or “Sema4” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) Sema4 Holdings and its subsidiaries following the consummation of the Business Combination.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. As such, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto as of and for the years ended December 31, 2021, 2020 and 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 21, 2021 filed on March 14, 2022 (the “Annual Report”). The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments that are necessary to state fairly the results for the interim periods presented. Interim results are not necessarily indicative of the results of operations or cash flows for a full year or any subsequent interim period. The Company’s historical financial information includes costs of certain services historically provided by Icahn School of Medicine at Mount Sinai (“ISMMS”) pursuant to the Transition Services Agreement ("TSA") and service agreements. As discussed in the Company’s Annual Report, the Company identified the misclassification of certain expenses and out of period adjustments generally related to the recognition of cost of services. The impact of these adjustments were disclosed in the Company’s Annual Report and are reflected in the condensed consolidated statements of operations and comprehensive loss, condensed consolidated statement of redeemable convertible preferred stock and stockholders’ equity (deficit) and condensed consolidated statements of cash flows for the period ended March 31, 2021. Although the Company has incurred recurring losses in each year since inception, the Company expects its cash and cash equivalents will be sufficient to fund operations for at least the next twelve months from the date of filing of this Form 10-Q. Segment Information The Company operates and manages its business as one reportable operating segment based on how the Chief Executive Officer, who is the Company’s chief operating decision maker (“CODM”), assesses performance and allocates resources across the business. Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, the capitalization of software costs and the valuation of stock-based awards, inventory, earn-out contingent liability and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions. Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash and cash equivalents are deposited with high-quality financial institutions. The Company has balances in financial institutions that exceed federal depository insurance limits. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating the concentration of credit risk. Significant customers and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of March 31, 2022 and December 31, 2021 were primarily from large managed care insurance companies and a reference laboratory. There was no individual patient that accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate customer credit risk. For each significant payor, revenue as a percentage of total revenues and accounts receivable as a percentage of total accounts receivable are as follows: Revenue Accounts Receivable Three months ended March 31, As of March 31, As of December 31, 2022 2021 2022 2021 Payor A 24% 14% 26% 15% Payor B * * 19% 15% Payor C * 12% * * Payor D 10% 12% 11% * *less than 10% The Company is subject to a concentration of risk from a limited number of suppliers for certain reagents and laboratory supplies. One supplier accounted for approximately 13% and 11% for the three months ended March 31, 2022 and 2021, respectively. This risk is managed by maintaining a target quantity of surplus stock. Impact of COVID-19 Beginning in April 2020, the Company’s diagnostic test volumes decreased significantly as compared to the prior year as a result of the initial outbreak of the COVID-19 pandemic and the related limitations and priorities across the healthcare system. In response, beginning in May 2020, the Company entered into several service agreements with state governments and healthcare institutions to provide testing for the presence of COVID-19 variants. While test volumes have since improved, the Company continues to experience changes in the mix of tests due to the impact of the COVID-19 pandemic. COVID-19 could continue to have a material impact on the Company’s results of operations, cash flows and financial condition for the foreseeable future. In March 2020, the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”) was signed into law which was a stimulus bill that, among other things, provided assistance to qualifying businesses and individuals and included funding for the healthcare system. During 2020, as part of the stimulus provided by the CARES Act, the Company received $5.4 million, comprised of $2.6 million received under the Provider Relief Fund (“PRF”) distribution and $2.8 million received under the Employee Retention Credit (“ERC”) distribution which was recorded in other current liabilities and reflected in this balance as of March 31, 2022 and December 31, 2021. During the three months ended March 31, 2021, the Company received an additional $5.6 million under the PRF distribution, which was recognized in other income in the condensed consolidated statements of operations and comprehensive loss. Additionally, under the CARES Act, the Company deferred payment of U.S. social security taxes in 2020. As a result, $3.8 million of employer payroll tax payments were initially deferred as of December 31, 2020 with $1.9 million paid in December 2021 and the remaining $1.9 million payment will be made in December 2022. As of March 31, 2022, the remaining payable is recorded in other current liabilities. Following the Company’s announcement that it would discontinue COVID-19 testing services by March 31, 2022, the Company no longer provides COVID-19 testing services. During the three months ended March 31, 2022, the Company wrote off an accounts receivable balance of $0.5 million related to COVID-19 testing services. Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of amounts invested in money market funds. Carrying values of cash equivalents approximate fair value due to the short-term nature of these instruments. The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the same amounts shown on the condensed consolidated statements of cash flows (in thousands): As of March 31, 2022 As of December 31, 2021 Cash and cash equivalents $ 315,002 $ 400,569 Restricted cash 900 900 Total $ 315,902 $ 401,469 Restricted cash as of March 31, 2022 consists of money market deposit accounts that secure an irrevocable standby letter of credit that serves as collateral for security deposit operating leases (see Note 9, “Leases” ). Warrant Liability As of the consummation of the Prior Merger in July 2021, there were 21,995,000 warrants to purchase shares of Class A common stock outstanding, including 14,758,333 public warrants and 7,236,667 private placement warrants. As of December 31, 2021, there were 21,994,972 warrants to purchase shares of Class A common stock outstanding, including 14,758,305 public warrants and 7,236,667 private placement warrants outstanding. Each warrant expires five years after the Business Combination or earlier upon redemption or liquidation, and entitles the holder to purchase one share of Class A common stock at an exercise price of $11.50 per share, subject to adjustment, at any time commencing on September 4, 2021. The Company may redeem the outstanding public warrants if the price per share of the Class A common stock equals or exceeds $18.00 as described below: • in whole and not in part; • at a price of $0.01 per public warrant; • upon not less than 30 days’ prior written notice of redemption to each warrant holder; and • if, and only if, the closing price of the Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending three trading days before sending the notice of redemption to warrant holders. The Company may redeem the outstanding public warrants if the price per share of the common stock equals or exceeds $10.00 as described below: • in whole and not in part; • at $0.10 per warrant upon a minimum of 30 days’ prior written notice of redemption provided that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the fair market value of the common stock; • if, and only if, the closing price of the Class A common stock equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within the 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders; and • if the closing price of the common stock for any 20 trading days within a 30-trading day period ending three trading days before the Company sends notice of redemption to the warrant holders is less than $18.00 per share (as adjusted), the private placement warrants must also be concurrently called for redemption on the same terms as the outstanding public warrants, as described above. The private placement warrants were issued to CMLS Holdings, LLC, Mr. Munib Islam, Dr. Emily Leproust and Mr. Nat Turner, and are identical to the public warrants underlying the units sold in the initial public offering, except that (1) the private placement warrants and the common stock issuable upon the exercise of the private placement warrants would not be transferable, assignable or salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (2) the private placement warrants are exercisable on a cashless basis, (3) the private placement warrants are non-redeemable (except as described above, upon a redemption of warrants when the price per share of Class A common stock equals or exceeds $10.00) so long as they are held by the initial purchasers or their permitted transferees, and (4) the holders of the private placement warrants and the common stock issuable upon the exercise of the private placement warrants have certain registration rights. If the private placement warrants are held by someone other than the initial purchasers or their permitted transferees, the private placement warrants will be redeemable by the Company and exercisable by such holders on the same basis as the public warrants. The Company accounts for warrants as liability-classified instruments based on an assessment of the warrant terms and applicable authoritative guidance in accordance with ASC 480-Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815-Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether the warrants meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815. This assessment is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. Earn-out contingent liability In connection with the Prior Merger, all Legacy Sema4 stockholders and option holders at that time became entitled to a pro rata share of 19,021,576 earn-out shares and earn-out RSUs. Based on an assessment of the earn-out shares for the Legacy Sema4 stockholders, the Company considered ASC 480 and ASC 815 and accounted for the earn-out shares as a liability. The Company subsequently measures the fair value of the liability at each reporting period and reports the changes in fair value recorded as a component of other income (expense), net in the condensed consolidated statements of operations and comprehensive loss. The Company determined the fair value of the earn-out shares issued to the Legacy Sema4 stockholders as of March 31, 2022 was $3.4 million. As for the earn-out RSUs for the Legacy Sema4 option holders, a total of 2.7 million RSUs were granted on December 9, 2021. The vesting of such arrangement is conditioned on the satisfaction of both a service requirement and on the satisfaction of a market-based requirement. The market-based requirement would be achieved if the Company’s stock price is greater than or equal to $13 (Triggering Event I), $15 (Triggering Event II) and $18 (Triggering Event III) during the applicable performance period, based on the volume-weighted average price for a period of at least 20 days out of 30 consecutive trading days. Therefore, the Company accounts for this arrangement in accordance with ASC 718- Compensation — Stock Compensation (“ASC 718”) and stock-based compensation expense is recognized over the longer of the expected achievement period for the market-based requirement and the service requirement. The Company recorded $0.5 million of stock-based compensation expense in relation to the earn-out RSUs for the quarter ended March 31, 2022. In the event that any earn-out RSUs that are forfeited as a result of a failure to achieve the service requirement, the underlying shares will be reallocated on an annual basis to the Legacy Sema4 stockholders and to the Legacy Sema4 option holders who remain employed as of the date of such reallocation. The Company accounts for the re-allocations to Legacy Sema4 option holders as new grants. The estimated fair value of the earn-out is determined using a Monte Carlo valuation analysis. Capitalized Internal-Use Software Costs The Company capitalizes certain costs incurred related to the development of its software applications for internal use during the application development state. If a project constitutes an enhancement to existing software, the Company assesses whether the enhancement creates additional functionality to the software, thus qualifying the work incurred for capitalization. Costs incurred prior to meeting these criteria together with costs incurred for training and maintenance are expensed as incurred. Once the project is available for general release, capitalization ceases and the Company estimates the useful life of the asset and begins amortization. Restructuring Costs During the three months ended March 31, 2022, the Company’s Compensation Committee of the Board of Directors approved by written consent dated February 17, 2022 a restructuring plan which was executed by management and $2.7 million of restructuring charges were incurred and recorded in connection therewith. These costs include severance packages offered to the employees impacted by the plan and third party consulting costs. Additionally, as discussed in the “Note 14—Subsequent Events”, the Board of Directors approved additional headcount reductions in an effort to streamline operations and the Company expects to recognize expenses of $5.4 million during the second quarter of 2022. Emerging Growth Company The Company is an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012. As such, the Company is eligible for exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including reduced reporting and extended transition periods to comply with new or revised accounting standards for public business entities. The Company has elected to avail itself of this exemption and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. Recently Adopted Accounting Pronouncements in the First Quarter of 2022 In February 2016, the FASB issued ASU 2016-02, Leases (“Topic 842”), which requires lessees to recognize right-of-use assets and lease liabilities for most leases on their balance sheets. Expense recognition for lessees under ASC 842 is similar to current lease accounting. ASC 842 requires enhanced disclosures to help the financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted ASC 842 as of January 1, 2022, utilizing the modified retrospective adoption approach. In transition to the ASC 842, the Company elected to use the package of practical expedients permitted under the transition guidance that allowed us to not reassess: (i) whether any expired or existing contracts are or contain leases, (ii) the lease classification for any expired or existing leases, or (iii) initial direct costs for any existing leases. Additionally, the Company did not elect the hindsight practical expedient which would have permitted the use of hindsight in determining the lease term and assessing impairment. The Company elected to combine lease and non-lease components that are fixed and also elected not to recognize right-of-use assets and lease liabilities for leases with terms of 12 months or less (“short-term leases”). The adoption of the ASC 842 as of January 1, 2022, resulted in the recognition of operating lease right-of-use assets and operating lease liabilities of $39.2 million and $42.2 million, respectively. The adoption did not have material impact on finance leases. The adoption did not have material impact on the condensed consolidated statements of operations and comprehensive loss. Refer to “Note 9 Leases” for a discussion of the Company’s lease accounting following the adoption of ASC 842. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities About Government Assistance, which requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The Company adopted ASU 2021-10 effective January 1, 2022. The Company did not receive any such grants during the three months ended March 31, 2022. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The new credit losses standard changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, contract assets recognized as a result of applying ASC 606, loans and certain other instruments, entities will be required to use a new forward looking “expected loss” model that generally will result in earlier recognition of credit losses than under today’s incurred loss model. As an emerging growth company, ASU 2016-13 is effective for annual periods beginning after December 15, 2022, with early adoption permitted. Application of the amendments is through a cumulative-effect adjustment to the opening retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements and related disclosures.

Business Combination

Business Combination	3 Months Ended
	Mar. 31, 2022
Business Combination and Asset Acquisition [Abstract]
Business Combination	Business Combination As discussed in Note 1, on July 22, 2021, the Company consummated the Business Combination and received net cash proceeds of $510.0 million. Pursuant to the Business Combination, the following occurred: • Holders of 10,188 shares of CMLS’s Class A common stock sold in its initial public offering (the “public shares”) exercised their right to have such shares redeemed for a full pro rata portion of the trust account holding the proceeds from CMLS’s initial public offering (the “IPO”), which was approximately $10.00 per share, or $101,880 in aggregate. • Each share of CMLS’s Class B common stock was automatically converted into common stock of the Company. • Each share of the Legacy Sema4 Class B common stock was converted into 1/100th of a share of Legacy Sema4 Class A common stock and each share of Legacy Sema4 common stock and preferred stock was canceled and received a portion of the merger consideration, resulting in certain Legacy Sema4 stockholders receiving $230,665,220 of cash and the Legacy Sema4 stockholders receiving an aggregate of 178,336,298 shares of common stock of the Company. • Pursuant to subscription agreements entered into on February 9, 2021, certain investors agreed to subscribe for an aggregate of 35,000,000 newly-issued shares of common stock at a purchase price of $10.00 per share for an aggregate purchase price of $350,000,000 (the “PIPE Investment”). Concurrently with the closing of the Business Combination, the Company consummated the PIPE Investment. • After giving effect to the Prior Merger, the redemption of public shares and the conversion of the CMLS Class B common stock as described above, and the consummation of the PIPE Investment, there were 240,190,402 shares of the Company’s common stock issued and outstanding. In 2021, the Company recorded $51.8 million of transaction costs which consisted of direct, incremental legal, professional, accounting, and other third-party fees that were directly related to the execution of the Prior Merger in additional paid-in capital. Upon consummation of the Prior Merger, $9.0 million of the transaction costs relates to costs incurred by Legacy Sema4 and reclassed to offset against equity from prepaid expense and other current assets.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Diagnostic Revenue The Company’s diagnostic test revenue contracts typically consist of a single performance obligation to deliver diagnostic testing services to the ordering facility or patient and therefore allocation of the contract transaction price is generally not applicable. Revenue from diagnostic testing services is recorded at the estimated transaction price, subject to the constraint for variable consideration, upon transfer of control of the service. Control over diagnostic testing services is generally transferred at a point in time when the customer obtains control of the promised service which is upon delivery of the test. Other Revenue The Company enters into both short-term and long-term project-based collaboration and service agreements with third parties, whereby the Company provides diagnostic testing, research and related data aggregation reporting services. The consideration to which the Company is entitled pursuant to its collaboration and service agreements includes non-refundable upfront payments, fixed and variable payments based upon the achievement of certain milestones during the contract term. Non-refundable upfront payments are generally received in advance of performing the services and, therefore, are recorded as a contract liability upon receipt. Fixed and variable milestone payments are included in the transaction price only when it is probable that doing so will not result in a significant reversal of cumulative revenue recognized when the uncertainty associated with the milestone is subsequently resolved. Revenue for such collaboration and service agreements is recognized over time using an input measure based on costs incurred to satisfy the performance obligation. Disaggregated revenue The following table summarizes the Company’s disaggregated revenue by payor category (in thousands): Three months ended March 31, 2022 2021 Diagnostic test revenue Patients with third-party insurance $ 47,462 $ 46,197 Institutional customers 4,031 15,664 Self-pay patients 1,002 899 Total diagnostic test revenue 52,495 62,760 Other revenue 1,446 1,441 Total $ 53,941 $ 64,201 Reassessment of variable consideration Subsequent changes to the estimate of the transaction price, determined on a portfolio basis when applicable, are generally recorded as adjustments to revenue in the period of the change. The Company updates estimated variable consideration quarterly. For the three months ended March 31, 2022, the quarterly change in estimate resulted in a net $3.6 million increase to revenue for tests in which the performance obligation of delivering the test results was met in prior periods. The change in estimate is a result of changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third party payors. The quarterly change in estimate did not result in material adjustments to the Company’s previously reported revenue or accounts receivable amounts. Remaining performance obligations For certain long-term collaboration service agreements with original expected durations of more than one year, the Company’s obligations pursuant to such agreement represents partially unsatisfied performance obligations as of March 31, 2022. The revenues under the agreements are estimated to be approximately $10.3 million. The Company expects to recognize the majority of this revenue over the next 3 years. Contract assets and liabilities Contract assets consist of the Company’s right to consideration that is conditional upon its future performance. Contract assets arise in collaboration and service agreements for which revenue is recognized over time but the Company’s right to bill the customer is contingent upon the achievement of contractually-defined milestones. Contract liabilities consist of customer payments in excess of revenues recognized. For collaboration and service agreements, the Company assesses the performance obligations and recognizes contract liabilities as current or non-current based upon forecasted performance. A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below (in thousands): Contract Assets Contract December 31, 2021 $ 3,296 $ 3,769 Contract asset additions 453 — Customer prepayments — 350 Revenue recognized — (304) March 31, 2022 $ 3,749 $ 3,815 The Company presents contract assets and contract liabilities with respect to customer contracts on a net basis on its condensed consolidated balance sheets. As of March 31, 2022 and December 31, 2021, $0.1 million and $0.5 million is recorded as current contract liabilities, respectively. Revenues recognized for the three months ended March 31, 2022 and March 31, 2021 that were included in the contract liability balance at the beginning of each period were $0.5 million and $0.5 million, respectively. Costs to fulfill contracts Costs associated with fulfilling the Company’s performance obligations pursuant to its collaboration service agreements include costs for services that are subcontracted to ISMMS. Amounts prepaid are expensed in line with the pattern of revenue recognition. Prepayment of amounts prior to the costs being incurred are recognized on the condensed consolidated balance sheets as current or non-current based upon forecasted performance. As of March 31, 2022 and December 31, 2021, the Company had outstanding deferred costs to fulfill contracts of $1.5 million and $1.8 million, respectively. As of March 31, 2022 and December 31, 2021, all outstanding deferred costs were recorded as other current assets. Amortization of deferred costs was $0.3 million and $0.3 million for the three months ended March 31, 2022 and 2021, respectively. The amortization of these costs is recorded in the cost of services on the condensed consolidated statements of operations and comprehensive loss.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Financial assets and liabilities are recorded at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. The Company determines the fair value of its financial instruments based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. The following hierarchy lists three levels of fair value based on the extent to which inputs used in measuring fair value are observable in the market: Level 1: Observable inputs such as quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. Level 2: Observable inputs such as quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active or model-derived valuations whose significant inputs are observable. Level 3: Unobservable inputs that are significant to the measurement of fair value but are supported by little to no market data. The Company’s financial assets and liabilities consist of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, accrued liabilities, finance leases, warrant liability, earn-out contingent liability and long- term debt. The Company’s cash and cash equivalents, restricted cash, accounts receivable, accounts payable and accrued liabilities approximate their fair value due to the relatively short-term nature of these accounts. The Company’s finance leases are classified within Level 1 of the fair value hierarchy because such finance lease agreements bear interest at rates for instruments with similar characteristics; accordingly, the carrying value of these liabilities approximate their fair values. The Company’s loan from the Connecticut Department of Economic and Community Development is classified within Level 2 of the fair value hierarchy. As of March 31, 2022, the long-term debt was recorded at its carrying value of $11.0 million in the condensed consolidated balance sheet. The fair value was $9.5 million, which is estimated based on discounted cash flows using the yields of similar debt instruments of other companies with similar credit profiles. The following tables set forth the fair value of financial instruments that were measured at fair value on a recurring basis (in thousands): As of March 31, 2022 Total Level 1 Level 2 Level 3 Financial Assets: Money market funds $ 62,282 $ 62,282 $ — $ — Total financial assets $ 62,282 $ 62,282 $ — $ — Financial Liabilities: Public warrant liability $ 10,183 $ 10,183 $ — $ — Private warrant liability 4,993 — 4,993 — Earn-out contingent liability 3,432 — — 3,432 Total financial liabilities $ 18,608 $ 10,183 $ 4,993 $ 3,432 As of December 31, 2021 Total Level 1 Level 2 Level 3 Financial Assets: Money market funds $ 385,370 $ 385,370 $ — $ — Total financial assets $ 385,370 $ 385,370 $ — $ — Financial Liabilities: Public warrant liability $ 14,463 $ 14,463 $ — $ — Private warrant liability 7,092 — 7,092 — Earn-out contingent liability 10,244 — — 10,244 Total financial liabilities $ 31,799 $ 14,463 $ 7,092 $ 10,244 The Company’s outstanding warrants include publicly-traded warrants (the “Public Warrants”) which were originally issued in the IPO and warrants sold in a private placement to CMLS Holdings LLC (the “Private Warrants”). The Company evaluated its warrants under ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, and concluded that they do not meet the criteria to be classified in stockholders’ equity. Since the Public Warrants and Private Warrants meet the definition of a derivative under ASC 815, the Company recorded these warrants as non-current liabilities on the balance sheet at fair value upon the closing of the Business Combination, with subsequent changes in their respective fair values recognized in other income (expense), net on the condensed consolidated statements of operations and comprehensive loss at each reporting date. As of March 31, 2022, the Public Warrants are classified within Level 1 of the fair value hierarchy as they are traded in active markets. The Private Warrants are classified within Level 2 of the fair value hierarchy as management determined the fair value of each Private Warrant is the same as that of a Public Warrant because the terms are substantially the same. The contingent obligation to issue earn-out shares for Legacy Sema4 stockholders was accounted for as a liability and required remeasurement at each reporting date. The estimated fair value of the total earn-out shares as of March 31, 2022 is determined based on a Monte Carlo simulation valuation model. The fair value of the earn-out contingent liability is sensitive to expected volatility estimated based on selected guideline public companies’ stock prices, the Company’s implied volatility and Company’s common stock price which is sensitive to changes in the forecasts of earnings and/or the relevant operating metrics. The key assumptions utilized in determining the valuation as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 December 31, 2021 Stock price $3.07 $4.46 Expected volatility 72.5% 62.5% Expected term (in years) 1.3 1.6 Risk-free interest rate 1.83% 0.58% The earn-out contingent liability is categorized as Level 3 of the fair value hierarchy as the Company utilizes unobservable inputs in estimating volatility rate. The fair value determined and recorded as of December 31, 2021 was $10.2 million and during the three months ended March 31, 2022 a gain of $6.8 million was recorded in the change in fair market value of warrant and earn-out contingent liability in the condensed consolidated statements of operations and comprehensive loss based on re-measurement performed as of the period end date. There were no transfers between Level 1, Level 2 and Level 3 during the periods presented.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Property and equipment, net consisted of the following (in thousands): As of March 31, As of December 31, Laboratory equipment $ 27,838 $ 28,552 Equipment under finance leases 21,384 21,384 Leasehold improvements 21,915 21,905 Capitalized software 27,797 25,693 Building under finance lease 6,276 6,276 Construction in-progress 2,709 940 Computer equipment 7,536 6,634 Furniture, fixtures and other equipment 3,230 3,241 Total property and equipment 118,685 114,625 Less: accumulated depreciation and amortization (57,709) (51,906) Property and equipment, net $ 60,976 $ 62,719 For the three months ended March 31, 2022 and 2021, depreciation and amortization expense was $5.8 million and $4.9 million. This included software amortization expense of $1.6 million and $1.2 million for the three months ended March 31, 2022 and 2021. Depreciation and amortization expense is included within the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2022 2021 Cost of services $ 2,816 $ 3,058 Research and development 1,849 1,251 Selling and marketing 1 — General and administrative 1,137 593 Total depreciation and amortization expenses $ 5,803 $ 4,902

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions For three months ended March 31, 2022 and 2021, the Company incurred certain related party costs. There were no expenses recognized under the TSA for the three months ended March 31, 2022 and $1.4 million for the three months ended March 31, 2021 which is presented within related party expenses in the condensed consolidated statements of operations and comprehensive loss. The Company had no TSA payables due to ISMMS as of March 31, 2022 and December 31, 2021. Expenses recognized pursuant to other service arrangements with ISMMS, including certain sub-lease arrangements the Company has through ISMMS, totaled $1.9 million and $0.7 million for the three months ended March 31, 2022 and 2021, respectively. These amounts include certain lease expenses the Company incurs and pay to ISMMS for certain sub-lease arrangements. They are included in either cost of services or related party expenses on the condensed consolidated statements of operations and comprehensive loss depending on the particular activity to which the costs relate. Payables due to ISMMS for the other service arrangements were $2.5 million $2.6 million as of March 31, 2022 and December 31, 2021, respectively. These amounts include unpaid lease payments the Company accrued for the payments to be made to ISMMS and are included within due to related parties on the Company’s condensed consolidated balance sheets. Additionally, since the closing of the Prior Merger in July 2021 the Company has purchased $0.7 million of diagnostic testing kits and materials of which $0.4 million was recorded in cost of services for the three months ended March 31, 2022 from an affiliate of a member of the Board of Directors who has served in the role since July 2021. The prices paid represent market rates. Payables due were $0.7 million and $0.1 million as of March 31, 2022 and December 31, 2021, respectively. Total related party costs are included within cost of services and related party expenses in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2022 2021 Cost of services $ 1,056 $ 278 Related party expenses 1,284 1,797 Total related party costs $ 2,340 $ 2,075

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Long-Term Debt	Long-Term Debt Loan and Security Agreement (the “SVB Agreement”) On November 15, 2021, the Company and Sema4 OpCo, Inc. (together, the “Borrower”) entered into a Loan and Security Agreement (the “SVB Agreement”) with Silicon Valley Bank (“SVB”). The SVB Agreement provides for a revolving credit facility (the “Revolver”) up to an aggregate principal amount of $125.0 million, including a sublimit of $20.0 million for Letters of Credit (as such terms are defined in the SVB Agreement). The outstanding principal amount of any Advance (as such term is defined in the SVB Agreement) will bear interest at a floating rate per annum equal to the greater of (1) 4.00% and (2) the Prime Rate plus the Prime Rate Margin. The Revolver will mature on November 15, 2024. In connection with entering into the SVB agreement, the Company paid $0.5 million in debt issuance costs during 2021. The Company will pay an additional $0.5 million in fees to SVB at each anniversary of the SVB Agreement date for a total of $1.0 million and these fees are recorded in other current liabilities and other liabilities in the condensed consolidated balance sheets as of March 31, 2022. These costs are capitalized and amortized on a straight-line basis over the contractual term. Any unused fees charged on the Revolver is expensed as incurred. The obligations under the SVB Agreement are secured by a first priority perfected security interest in substantially all of the Borrower’s assets except for (i) Governmental Collection Accounts (as defined in the SVB Agreement), (ii) more than 65% of the presently existing and thereafter arising issued and outstanding shares of capital stock owned by Borrowers in a Foreign Subsidiary (as such term is defined in the SVB Agreement) and (iii) intellectual property pursuant to the terms of the SVB Agreement. The SVB Agreement contains affirmative and negative covenants, including, among other things, restrictions on indebtedness, liens, investments, mergers, dispositions, and dividends and other distributions. The SVB Agreement requires the Borrower to comply with certain financial covenants if Liquidity (as such term is defined in the SVB Agreement) falls below $135.0 million. These financial covenants include (i) a minimum Adjusted Quick Ratio (as such term is defined in the SVB Agreement) and (ii) the achievement of certain minimum revenue targets. On a monthly basis, the Borrowers would be required to maintain a minimum Adjusted Quick Ratio of greater than or equal to 1.25 to 1.0. The Borrower must also maintain certain trailing six-month minimum revenue targets through maturity if outstanding borrowings under the Revolver exceed $50.0 million. The SVB Agreement also includes customary events of default, including failure to pay principal, interest or certain other amounts when due, material inaccuracy of representations and warranties, violation of covenants, certain bankruptcy and insolvency events, certain undischarged judgments, material invalidity of guarantees or grant of security interest, material adverse change, and involuntary delisting from the Nasdaq Stock Market, in certain cases subject to certain thresholds and grace periods. If one or more events of default occurs and continues beyond any applicable cure period, SVB may, without notice or demand to the Borrower, terminate its commitment to make further loans and declare all of the obligations of the Borrowers under the SVB Agreement to be immediately due and payable. The Company was in compliance with all covenants as of March 31, 2022. No amounts have been drawn under the SVB Agreement as of March 31, 2022. 2016 Funding Commitment In June 2017, ISMMS assigned a loan funding commitment from the Connecticut Department of Economic and Community Development (“DECD”) to the Company (as amended, the “DECD Loan Agreement”). The DECD Loan Agreement, provides for a total loan commitment of $15.5 million at a fixed annual interest rate of 2.0% for a term of 10 years. The Company is required to make interest-only payments through July 2023 and principal and interest payments commencing in August 2023. The final payment of principal and interest is due in July 2028. However, under the terms of the DECD Loan Agreement, the DECD may grant partial principal loan forgiveness of up to $12.3 million in the aggregate. Such forgiveness is contingent upon the Company achieving job creation and retention milestones and $7.3 million has been forgiven as of March 31, 2022. This commitment is collateralized by providing a security interest in certain machinery and equipment the Company acquired from ISMMS, as defined in a separate security agreement. The outstanding loan balance from the DECD Loan Agreement was $11.0 million as of March 31, 2022 and December 31, 2021. Maturities of Long-Term Debt As of March 31, 2022, long-term debt matures as follows (in thousands): 2022 (remainder of year) $ — 2023 875 2024 2,131 2025 2,174 2026 2,218 Thereafter 3,602 Total maturities of long-term debt 11,000 Less: current portion of long-term debt — Total long-term debt, net of current maturities $ 11,000 2020 Master Loan Agreement In August 2020, the Company entered into a loan and security agreement with a bank (the “Master Loan Agreement”), in which the Company received a loan of $6.3 million and deposited the proceeds into a deposit account held by the bank. The Company was required to make sixty consecutive monthly payments of principal and interest at a fixed monthly amount of $0.1 million beginning in November 2020. Interest payments were fixed at an annual interest rate of 4.75%. In July 2021, the Company terminated the Master Loan Agreement by paying off the full amount, including $5.4 million principal and interest and $0.1 million in early payment penalties assessed pursuant to the terms of the agreement. 2020 Master Lease Agreement In December 2020, the Company entered into a lease agreement with a lender whereby the Company agreed to sell certain equipment and immediately lease back the equipment, resulting in proceeds of $3.6 million. Per the terms of the agreement, a financial institution issued an irrevocable standby letter of credit to the lender for $3.6 million. The Company was required to make sixty consecutive monthly payments of principal and interest at a fixed monthly amount of $0.1 million beginning in February 2021. Interest payments were fixed at an annual interest rate of 3.54%. The Company was required to maintain an aggregate amount on deposit equal to at least 105% of the value of any outstanding letters of credit issued by the financial institution on the Company’s behalf. The letter of credit was required to be in place until all obligations had been paid in full. Further, the Company was required to furnish annual audited financial statements and other financial information to the lender on a regular basis. In July 2021, the Company terminated the Master Lease Agreement by paying off the full amount, including $3.3 million principal and interest and early payment penalties of $0.2 million assessed pursuant to the terms of the agreement.

Leases

Leases	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Leases	Leases Lease Accounting The Company enters into contracts in the normal course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception if it conveys the right to control the identified asset for a period of time in exchange for consideration. The Company classifies leases as operating or financing in nature. All lease liabilities are measured at the present value of the associated payments, discounted using the Company’s incremental borrowing rate determined based on the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for similar term and in a similar economic environment on a collateralized basis, unless there is a rate implicit in the lease that is readily determinable. Operating Leases The Company's operating lease arrangements are principally for office space and laboratory facilities. The Company’s headquarter lease was initially entered into via sub-lease agreements with ISMMS and a third party and they will expire in 2034. The agreements include escalating rent and rent-free period provisions. Pursuant to the terms of the lease agreement, the Company was required to have issued an irrevocable standby letter of credit to the lessor for $0.9 million, which was included in restricted cash on the condensed consolidated balance sheets as of March 31, 2022 and consolidated balance sheets as of December 31, 2021. In April 2019, the Company entered into a sublease agreement to rent a building to be used for office and laboratory facility (the “Stamford Lease”) for a base term of 325 months, expiring in October 2046. The Company has the option to renew the lease at the end of the initial base term for either one period of 10 years, or two periods of 5 years. There is also an early termination option in which the Company may cancel the lease after the 196th month with cancellation fees. At inception of the Stamford Lease, the value of the land was determined to be more than 25% of the total value and therefore the building is accounted for as a finance lease and the land as an operating lease. In January 2020, the Company entered into a lease agreement which expanded the Company’s existing laboratory facility in Branford, Connecticut. The lease commenced in February 2020 with a 10 year term. The lease includes escalating rent fees over the lease term. Finance Leases The Company enters into various finance lease agreements to obtain laboratory equipment that contain bargain purchase commitments at the end of the lease term. The leases are secured by the underlying equipment. As discussed above, the Company also leases a building used for office and laboratory space in which the building is accounted for as a finance lease and the land is as an operating lease. The interest rate used for the Stamford Lease is 13.1%, which is used to measure the operating and finance lease liability. The tables below present financial information associated with the Company’s leases. This information is only presented as of, and for the three months ended, March 31, 2022 because, the Company adopted the ASC 842 using a transition method that does not require application to periods prior to adoption (in thousands). Classification March 31, 2022 Assets Operating lease assets Operating lease right-of-use assets $ 38,417 Finance lease assets Property and Equipment, net 13,190 Total lease assets $ 51,607 Liabilities Current Operating Due to related parties $ 566 Short-term lease liabilities 1,892 Finance Due to related parties 304 Short-term lease liabilities 3,180 Non-current Operating Long-term lease liabilities 39,649 Finance Long-term lease liabilities 17,829 Total lease liabilities $ 63,420 Lease cost Three months ended March 31, 2022 Operating lease cost Operating lease cost $ 1,380 Short-term lease cost 169 Variable lease cost 127 Total operating lease cost $ 1,676 Finance lease cost Depreciation and amortization of leased assets $ 912 Interest on lease liabilities 552 Total finance lease cost $ 1,464 Total lease cost $ 3,140 Future minimum lease payments under non-cancellable leases as of March 31, 2022 are as follows: Maturity of lease liabilities Operating leases Finance leases Total 2022 (remainder of the year) $ 3,862 $ 3,808 $ 7,670 2023 4,338 3,584 7,922 2024 4,440 2,763 7,203 2025 4,835 2,451 7,286 2026 4,949 2,003 6,952 Thereafter 51,920 49,884 101,804 Total $ 74,344 $ 64,493 $ 138,837 Less: imputed interest $ (32,237) $ (43,180) $ (75,417) Present value of lease liabilities $ 42,107 $ 21,313 $ 63,420 Other information related to leases as of and the three months ended March 31, 2022 are as follows: March 31, 2022 Weighted-average remaining lease term (years) Operating leases 13.5 Finance leases 17.8 Weighted-average discount rate Operating leases 6.8% Finance leases 10.5% Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $1,236 Operating cash flows from finance leases $552 Financing cash flows from finance lease $862
Leases	Leases Lease Accounting The Company enters into contracts in the normal course of business and assesses whether any such contracts contain a lease. The Company determines if an arrangement is a lease at inception if it conveys the right to control the identified asset for a period of time in exchange for consideration. The Company classifies leases as operating or financing in nature. All lease liabilities are measured at the present value of the associated payments, discounted using the Company’s incremental borrowing rate determined based on the rate of interest that the Company would pay to borrow on a collateralized basis an amount equal to the lease payments for similar term and in a similar economic environment on a collateralized basis, unless there is a rate implicit in the lease that is readily determinable. Operating Leases The Company's operating lease arrangements are principally for office space and laboratory facilities. The Company’s headquarter lease was initially entered into via sub-lease agreements with ISMMS and a third party and they will expire in 2034. The agreements include escalating rent and rent-free period provisions. Pursuant to the terms of the lease agreement, the Company was required to have issued an irrevocable standby letter of credit to the lessor for $0.9 million, which was included in restricted cash on the condensed consolidated balance sheets as of March 31, 2022 and consolidated balance sheets as of December 31, 2021. In April 2019, the Company entered into a sublease agreement to rent a building to be used for office and laboratory facility (the “Stamford Lease”) for a base term of 325 months, expiring in October 2046. The Company has the option to renew the lease at the end of the initial base term for either one period of 10 years, or two periods of 5 years. There is also an early termination option in which the Company may cancel the lease after the 196th month with cancellation fees. At inception of the Stamford Lease, the value of the land was determined to be more than 25% of the total value and therefore the building is accounted for as a finance lease and the land as an operating lease. In January 2020, the Company entered into a lease agreement which expanded the Company’s existing laboratory facility in Branford, Connecticut. The lease commenced in February 2020 with a 10 year term. The lease includes escalating rent fees over the lease term. Finance Leases The Company enters into various finance lease agreements to obtain laboratory equipment that contain bargain purchase commitments at the end of the lease term. The leases are secured by the underlying equipment. As discussed above, the Company also leases a building used for office and laboratory space in which the building is accounted for as a finance lease and the land is as an operating lease. The interest rate used for the Stamford Lease is 13.1%, which is used to measure the operating and finance lease liability. The tables below present financial information associated with the Company’s leases. This information is only presented as of, and for the three months ended, March 31, 2022 because, the Company adopted the ASC 842 using a transition method that does not require application to periods prior to adoption (in thousands). Classification March 31, 2022 Assets Operating lease assets Operating lease right-of-use assets $ 38,417 Finance lease assets Property and Equipment, net 13,190 Total lease assets $ 51,607 Liabilities Current Operating Due to related parties $ 566 Short-term lease liabilities 1,892 Finance Due to related parties 304 Short-term lease liabilities 3,180 Non-current Operating Long-term lease liabilities 39,649 Finance Long-term lease liabilities 17,829 Total lease liabilities $ 63,420 Lease cost Three months ended March 31, 2022 Operating lease cost Operating lease cost $ 1,380 Short-term lease cost 169 Variable lease cost 127 Total operating lease cost $ 1,676 Finance lease cost Depreciation and amortization of leased assets $ 912 Interest on lease liabilities 552 Total finance lease cost $ 1,464 Total lease cost $ 3,140 Future minimum lease payments under non-cancellable leases as of March 31, 2022 are as follows: Maturity of lease liabilities Operating leases Finance leases Total 2022 (remainder of the year) $ 3,862 $ 3,808 $ 7,670 2023 4,338 3,584 7,922 2024 4,440 2,763 7,203 2025 4,835 2,451 7,286 2026 4,949 2,003 6,952 Thereafter 51,920 49,884 101,804 Total $ 74,344 $ 64,493 $ 138,837 Less: imputed interest $ (32,237) $ (43,180) $ (75,417) Present value of lease liabilities $ 42,107 $ 21,313 $ 63,420 Other information related to leases as of and the three months ended March 31, 2022 are as follows: March 31, 2022 Weighted-average remaining lease term (years) Operating leases 13.5 Finance leases 17.8 Weighted-average discount rate Operating leases 6.8% Finance leases 10.5% Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $1,236 Operating cash flows from finance leases $552 Financing cash flows from finance lease $862

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Obligations In the normal course of business, the Company enters into various purchase commitments primarily related to material and service agreements, laboratory supplies and software. At March 31, 2022, the Company’s total future payments under noncancelable unconditional purchase commitments having a remaining term of over one year were $19.4 million. Contingencies The Company is a party to various actions and claims arising in the normal course of business. The Company does not believe that the outcome of these matters will have a material effect on the Company’s condensed consolidated financial position, results of operations or cash flows. However, no assurance can be given that the final outcome of such proceedings will not materially impact the Company’s condensed consolidated financial condition or results of operations.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation Stock Incentive Plans The Company’s 2017 Equity Incentive Plan (the “2017 Plan”), as amended in February 2018, allowed the grant of options, restricted stock awards, stock appreciation rights and restricted stock units. No options granted under the 2017 Plan are exercisable after 10 years from the date of grant, and option awards generally vest over a four-year period. The 2017 Plan was terminated in connection with the adoption of the Company's 2021 Equity Incentive Plan (the "2021 Plan"). Any awards granted under the 2017 Plan that remained outstanding as of the Closing Date and were converted into awards with respect to the Company’s Class A common stock in connection with the consummation of the Business Combination continue to be subject to the terms of the 2017 Plan and applicable award agreements, except for a modification of the repurchase provision, which is discussed further below. On July 22, 2021, in connection with the Business Combination, the 2021 Plan became effective and 32,734,983 authorized shares of Class A common stock were reserved for issuance thereunder. This Plan will be administered by the Compensation Committee of the Company’s Board of Directors, including determination of the vesting, exercisability and payment of the awards to be granted under this Plan. No awards granted under the 2021 Plan are exercisable after 10 years from the date of grant, and the awards granted under the 2021 Plan generally vest over a four-year period on a graded vesting basis. Employee Stock Purchase Plan The 2021 Employee Stock Purchase Plan (the “2021 ESPP”) became effective in connection with the Business Combination. The 2021 ESPP authorizes the issuance of shares of Class A common stock pursuant to purchase rights granted to employees. On each January 1 of each of 2022 through 2031, the aggregate number of shares of Class A common stock reserved for issuance under the 2021 Plan may be increased automatically by the number of shares equal to one percent (1%) of the total number of shares of all classes of common stock issued and outstanding immediately preceding December 31. The Company did not make any grants of purchase rights under the 2021 ESPP during the quarter ended March 31, 2022. A total of 7,229,799 shares of Class A common stock have been reserved for future issuance under the 2021 ESPP. Stock Option Activity Under the 2017 Plan, the Company had a call option to repurchase awards for cash from the plan participants upon termination of the participant’s employment or consulting agreement (the “2017 Plan Call Option”). The options granted under the 2017 plan were accounted for as liability awards due to the 2017 Plan Call Option. The Company had a history of repurchase practice and the intention to repurchase the vested options. Therefore, the fair value of the liability awards was remeasured at each reporting period until the stockholder bears the risks and rewards of equity ownership for a reasonable period of time, which the Company concludes is at least six months. Upon consummation of the Business Combination, the Company’s Board of Directors waived the Company’s right under the 2017 Plan Call Option to repurchase awards for cash from the plan participants upon termination of the participant’s employment or consulting agreement. As such, the Company modified the liability awards to equity awards and reclassified the modification date fair value of the awards to stockholders’ equity in the condensed consolidated financial statements as of July 22, 2021. All stock options granted under the 2021 Plan are accounted for as equity awards. The following summarizes the stock option activity, which reflects the conversion of the options granted under the 2017 Plan into awards with respect to the Company Class A common stock in connection with the consummation of the Business Combination (in thousands, except share and per share amounts): Stock Options Outstanding Weighted Average Exercise Price Balance at December 31, 2021 30,905,543 $ 1.24 Options granted 851,884 $ 3.37 Options exercised (2,108,502) $ 0.32 Options forfeited or canceled (759,629) $ 2.98 Balance at March 31, 2022 28,889,296 $ 1.33 Options exercisable at March 31, 2022 21,620,867 $ 0.54 As of March 31, 2022, unrecognized stock-based compensation cost related to the unvested portion of the Company’s stock options was $22.1 million, which is expected to be recognized on a graded-vesting basis over a weighted-average period of 1.5 years. The fair value of the stock option awards for the period ended March 31, 2022, and March 31, 2021 were estimated using the Black-Scholes option pricing model with the following assumptions: Three Months ended March 31, 2022 2021 Expected volatility 65.20% - 67.60% 68.50%- 75.60% Expected term (in years) 5.48-6.06 0.50- 1.75 Risk-free interest rate 1.65%-1.70% 0.05%- 0.16% Dividend yield — — Fair value of Class A common stock $3.29-$3.45 $4.57- $12.51 The Company estimated a volatility factor for the Company’s options based on analysis of historical share prices of a peer group of public companies. The Company did not rely on the volatility of the Company’s Class A common stock because its limited trading history. The Company estimated the expected term of options granted using the “simplified method,” which is the mid-point between the vesting date and the ending date of the contractual term. The Company did not rely on the historical holding periods of the Company’s options due to the limited availability of exercise data. The Company used a risk-free interest rate based on the U.S. Treasury yield curve in effect for bonds with maturities consistent with the expected term of the option. Restricted Stock Units (RSUs) The Company issued time-based RSUs to employees under the 2021 Plan. The RSUs automatically convert to shares of Class A common stock on a one-for-one basis as the awards vest. The Company measures the value of RSUs at fair value based on the closing price of the underlying Class A common stock on the grant date. The RSUs granted generally vest over a four year vesting period from the grant date, however, the Company also granted certain RSUs during the three months ended December 31, 2021, which were vesting beginning 12 months from the grant date and vesting immediately on the grant date. The following table summarizes the activity related to the Company's time-based RSUs: Restricted Stock Units Outstanding Weighted Average Grant Date Fair Value Per Unit Balance at December 31, 2021 12,589,558 $7.64 Restricted Stock Units granted 762,190 $3.48 Restricted Stock Units vested (398,369) $7.63 Restricted Stock Units forfeited (830,620) $7.62 Balance at March 31, 2022 12,122,759 $7.38 As of March 31, 2022, unrecognized stock-based compensation cost related to the unvested portion of the Company’s RSUs was $60.2 million, which is expected to be recognized on a graded-vesting basis over a weighted-average period of 1.6 years. Earn-out RSUs The grant date fair value determined for Triggering Event I, II and III was $1.82, $1.39 and $0.94 per unit, respectively. Any re-allocated RSUs due to the Sema4 Legacy option holders’ forfeiture activities during the three months ended March 31, 2022 were accounted for as new grants and the fair value determined for Triggering Event I, II and III was $0.29, $0.21 and $0.12 per unit, respectively. Based on the grant date fair value, the Company expects to record total expense related to the earn-out RSU awards of $2.7 million without considering the impact of the Sema4 Legacy option holders’ forfeiture activities. The Company expects to recognize the stock-compensation cost over the longer of the derived service period or service period. Stock Appreciation Rights (SAR) Activity The Company historically granted SAR to one employee and one consultant with exercise condition of a liquidation event. As a result of the Business Combination, settlement of the outstanding vested SARs in exchange for a cash payment and to cancel the outstanding unvested SARs was agreed upon and an expense of $3.8 million related to the vested SAR was recognized by the Company. There were no outstanding SARs as of March 31, 2022. During the three months ended March 31, 2022, the Company recorded a reversal of stock-based compensation of $5.2 million due to forfeiture activities upon employee terminations. Stock-based compensation expense for all awards granted and outstanding is included within the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2022 2021 Cost of services $ 1,381 $ 18,475 Research and development 4,341 38,187 Selling and marketing 2,825 18,688 General and administrative 9,012 89,612 Total stock-based compensation expense $ 17,559 $ 164,962

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income TaxesIncome taxes for the three months ended March 31, 2022 are recorded at the Company’s estimated annual effective income tax rate, subject to adjustments for discrete events, should they occur. The Company’s estimated annual effective tax rate was 0.0% for the three months ended March 31, 2022. The primary reconciling item between the federal statutory rate of 21.0% for these periods and the Company’s overall effective tax rate of 0.0% was related to the effects of the valuation allowance recorded against the full amount of its net deferred tax assets. A valuation allowance is required when it is more likely than not that some portion or all of the Company’s deferred tax assets will not be realized. The realization of deferred tax assets depends on the generation of sufficient future taxable income during the period in which the Company’s related temporary differences become deductible. The Company has recorded a full valuation allowance against its net deferred tax assets as of March 31, 2022 since management believes that based on the earnings history of the Company, it is more likely than not that the benefits of these assets will not be realized.

Net Loss per Share

Net Loss per Share	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Net Loss per Share	Net Loss per Share Basic and diluted loss per share attributable to common stockholders was calculated as follows (amounts in thousands, except for share and per share amounts): Three months ended March 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (76,896) $ (191,775) Denominator: Denominator for basic and diluted earnings per share-weighted-average common shares 244,368,743 549,778 Basic and diluted loss per share $ (0.31) $ (348.82) As a result of the Prior Merger, the Company has retroactively adjusted the weighted-average number of shares of common stock outstanding prior to the Prior Merger by multiplying them by the conversion ratio of 123.8339 used to determine the number of shares of common stock into which they converted. The common stock issued as a result of the redeemable convertible preferred stock conversion upon closing of the Prior Merger was included in the basic and diluted earnings/(loss) per share calculation on a prospective basis. Prior to the consummation of the Prior Merger, the Company applied the two-class method to calculate its basic and diluted net loss per share of common stock, as there were outstanding Class B common stock and redeemable convertible preferred stock that were participating securities. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. As the securities were all converted into Sema4 Holdings Class A common stock upon consummation of the Prior Merger, all outstanding Legacy Sema4 Class B common stock has been retroactively converted to the Sema4 Holdings Class A common stock. The following tables summarize the outstanding shares of potentially dilutive securities that were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been anti-dilutive: Three months ended March 31, 2022 2021 Outstanding options and RSUs to purchase Class A common stock 41,012,055 29,608,717 Outstanding warrants 21,994,972 — Outstanding earn-out shares 16,611,117 — Outstanding earn-out RSUs 2,410,459 — Redeemable convertible preferred stock (on an if-converted basis) — 171,535,214 Total 82,028,603 201,143,931

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events GeneDx Acquisition On April 29, 2022, the Company completed the acquisition (the “Acquisition”) of GeneDx LLC (“GeneDx”), from OPKO Health Inc. (“OPKO”). Sema4 acquired GeneDx for an upfront payment of $150 million in cash, subject to adjustment, plus 80 million shares of Sema4’s Class A common stock, with up to an additional $150 million payable if certain revenue-based milestones are achieved over the next two years (which will be payable in cash or shares of Sema4’s Class A common stock at Sema4’s discretion). Based on the closing stock price of Sema4’s Class A common stock as of April 29, 2022, the trading day on the closing of the transaction, the total upfront consideration represents approximately $322 million, subject to adjustment, and the total aggregate consideration including potential milestones is approximately $472 million. The transaction was announced on January 18, 2022 and the issuance of the shares of Sema4’s Class A common stock in connection with the acquisition, among other proposals, received approval from Sema4 stockholders on April 27, 2022. Subscription Agreements and Acquisition PIPE Investment (Private Placement) In connection with the Acquisition of GeneDx, the Company also closed a private placement financing (the “Acquisition PIPE Investment”) in which it issued 50 million shares of Sema4’s Class A common stock at a price of $4.00 per share with a syndicate of institutional investors, receiving gross proceeds of $200 million. Restructuring On May 2, 2022, the Company’s Compensation Committee of the Board of Directors approved by written consent for the Company to implement an employee restructuring plan, which is intended to reduce costs and optimize its organizational and operational efficiency. The Company’s management executed the plan and expects to recognize expenses of $5.4 million during the second quarter of 2022. The costs primarily consist of the cost of benefits provided pursuant to the severance programs for the employees impacted by the plan and third party consulting costs expected to be incurred.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. As such, the accompanying unaudited condensed consolidated financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto as of and for the years ended December 31, 2021, 2020 and 2019 included in the Company’s Annual Report on Form 10-K for the year ended December 21, 2021 filed on March 14, 2022 (the “Annual Report”).
Segment Information	Segment Information The Company operates and manages its business as one reportable operating segment based on how the Chief Executive Officer, who is the Company’s chief operating decision maker (“CODM”), assesses performance and allocates resources across the business.
Use of Estimates	Use of Estimates The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, the capitalization of software costs and the valuation of stock-based awards, inventory, earn-out contingent liability and earn-out Restricted Stock Units (“RSUs”). Actual results could differ materially from those estimates, judgments and assumptions.
Concentration of Credit Risk and Other Risks and Uncertainties	Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company’s cash and cash equivalents are deposited with high-quality financial institutions. The Company has balances in financial institutions that exceed federal depository insurance limits. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents. The Company assesses both the self-pay patient and, if applicable, the third-party payor that reimburses the Company on the patient’s behalf when evaluating the concentration of credit risk. Significant customers and payors are those that represent more than 10% of the Company’s total revenues for the period or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of March 31, 2022 and December 31, 2021 were primarily from large managed care insurance companies and a reference laboratory. There was no individual patient that accounted for 10% or more of the Company’s revenue or accounts receivable for any of the periods presented. The Company does not require collateral as a means to mitigate customer credit risk.
Cash, Cash Equivalents and Restricted Cash	Cash, Cash Equivalents and Restricted Cash The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist of amounts invested in money market funds. Carrying values of cash equivalents approximate fair value due to the short-term nature of these instruments.
Capitalized Internal-Use Software Costs	Capitalized Internal-Use Software Costs The Company capitalizes certain costs incurred related to the development of its software applications for internal use during the application development state. If a project constitutes an enhancement to existing software, the Company assesses whether the enhancement creates additional functionality to the software, thus qualifying the work incurred for capitalization. Costs incurred prior to meeting these criteria together with costs incurred for training and maintenance are expensed as incurred. Once the project is available for general release, capitalization ceases and the Company estimates the useful life of the asset and begins amortization. Restructuring Costs During the three months ended March 31, 2022, the Company’s Compensation Committee of the Board of Directors approved by written consent dated February 17, 2022 a restructuring plan which was executed by management and
Recently Adopted Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements in the First Quarter of 2022 In February 2016, the FASB issued ASU 2016-02, Leases (“Topic 842”), which requires lessees to recognize right-of-use assets and lease liabilities for most leases on their balance sheets. Expense recognition for lessees under ASC 842 is similar to current lease accounting. ASC 842 requires enhanced disclosures to help the financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The Company adopted ASC 842 as of January 1, 2022, utilizing the modified retrospective adoption approach. In transition to the ASC 842, the Company elected to use the package of practical expedients permitted under the transition guidance that allowed us to not reassess: (i) whether any expired or existing contracts are or contain leases, (ii) the lease classification for any expired or existing leases, or (iii) initial direct costs for any existing leases. Additionally, the Company did not elect the hindsight practical expedient which would have permitted the use of hindsight in determining the lease term and assessing impairment. The Company elected to combine lease and non-lease components that are fixed and also elected not to recognize right-of-use assets and lease liabilities for leases with terms of 12 months or less (“short-term leases”). The adoption of the ASC 842 as of January 1, 2022, resulted in the recognition of operating lease right-of-use assets and operating lease liabilities of $39.2 million and $42.2 million, respectively. The adoption did not have material impact on finance leases. The adoption did not have material impact on the condensed consolidated statements of operations and comprehensive loss. Refer to “Note 9 Leases” for a discussion of the Company’s lease accounting following the adoption of ASC 842. In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832), Disclosures by Business Entities About Government Assistance, which requires entities to provide disclosures on material government assistance transactions for annual reporting periods. The disclosures include information around the nature of the assistance, the related accounting policies used to account for government assistance, the effect of government assistance on the entity’s financial statements, and any significant terms and conditions of the agreements, including commitments and contingencies. The Company adopted ASU 2021-10 effective January 1, 2022. The Company did not receive any such grants during the three months ended March 31, 2022. Recently Issued Accounting Pronouncements Not Yet Adopted In June 2016, the FASB issued ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). The new credit losses standard changes the impairment model for most financial assets and certain other instruments. For trade and other receivables, contract assets recognized as a result of applying ASC 606, loans and certain other instruments, entities will be required to use a new forward looking “expected loss” model that generally will result in earlier recognition of credit losses than under today’s incurred loss model. As an emerging growth company, ASU 2016-13 is effective for annual periods beginning after December 15, 2022, with early adoption permitted. Application of the amendments is through a cumulative-effect adjustment to the opening retained earnings as of the beginning of the first reporting period in which the guidance is effective. The Company is currently evaluating the impact of the new guidance on its consolidated financial statements and related disclosures.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Revenue and accounts receivable concentration percentages	For each significant payor, revenue as a percentage of total revenues and accounts receivable as a percentage of total accounts receivable are as follows: Revenue Accounts Receivable Three months ended March 31, As of March 31, As of December 31, 2022 2021 2022 2021 Payor A 24% 14% 26% 15% Payor B * * 19% 15% Payor C * 12% * * Payor D 10% 12% 11% * *less than 10%
Reconciliation of cash and cash equivalents	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the same amounts shown on the condensed consolidated statements of cash flows (in thousands): As of March 31, 2022 As of December 31, 2021 Cash and cash equivalents $ 315,002 $ 400,569 Restricted cash 900 900 Total $ 315,902 $ 401,469
Reconciliation of restricted cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported on the condensed consolidated balance sheets that sum to the total of the same amounts shown on the condensed consolidated statements of cash flows (in thousands): As of March 31, 2022 As of December 31, 2021 Cash and cash equivalents $ 315,002 $ 400,569 Restricted cash 900 900 Total $ 315,902 $ 401,469

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue disaggregated by type of customer	The following table summarizes the Company’s disaggregated revenue by payor category (in thousands): Three months ended March 31, 2022 2021 Diagnostic test revenue Patients with third-party insurance $ 47,462 $ 46,197 Institutional customers 4,031 15,664 Self-pay patients 1,002 899 Total diagnostic test revenue 52,495 62,760 Other revenue 1,446 1,441 Total $ 53,941 $ 64,201
Contract assets and contract liabilities	A reconciliation of the beginning and ending balances of contract assets and contract liabilities is shown in the table below (in thousands): Contract Assets Contract December 31, 2021 $ 3,296 $ 3,769 Contract asset additions 453 — Customer prepayments — 350 Revenue recognized — (304) March 31, 2022 $ 3,749 $ 3,815

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of fair value on a recurring basis	The following tables set forth the fair value of financial instruments that were measured at fair value on a recurring basis (in thousands): As of March 31, 2022 Total Level 1 Level 2 Level 3 Financial Assets: Money market funds $ 62,282 $ 62,282 $ — $ — Total financial assets $ 62,282 $ 62,282 $ — $ — Financial Liabilities: Public warrant liability $ 10,183 $ 10,183 $ — $ — Private warrant liability 4,993 — 4,993 — Earn-out contingent liability 3,432 — — 3,432 Total financial liabilities $ 18,608 $ 10,183 $ 4,993 $ 3,432 As of December 31, 2021 Total Level 1 Level 2 Level 3 Financial Assets: Money market funds $ 385,370 $ 385,370 $ — $ — Total financial assets $ 385,370 $ 385,370 $ — $ — Financial Liabilities: Public warrant liability $ 14,463 $ 14,463 $ — $ — Private warrant liability 7,092 — 7,092 — Earn-out contingent liability 10,244 — — 10,244 Total financial liabilities $ 31,799 $ 14,463 $ 7,092 $ 10,244
Schedule of measurement inputs and valuation techniques	The key assumptions utilized in determining the valuation as of March 31, 2022 and December 31, 2021 were as follows: March 31, 2022 December 31, 2021 Stock price $3.07 $4.46 Expected volatility 72.5% 62.5% Expected term (in years) 1.3 1.6 Risk-free interest rate 1.83% 0.58%

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and equipment and depreciation and amortization expense	Property and equipment, net consisted of the following (in thousands): As of March 31, As of December 31, Laboratory equipment $ 27,838 $ 28,552 Equipment under finance leases 21,384 21,384 Leasehold improvements 21,915 21,905 Capitalized software 27,797 25,693 Building under finance lease 6,276 6,276 Construction in-progress 2,709 940 Computer equipment 7,536 6,634 Furniture, fixtures and other equipment 3,230 3,241 Total property and equipment 118,685 114,625 Less: accumulated depreciation and amortization (57,709) (51,906) Property and equipment, net $ 60,976 $ 62,719 Three months ended March 31, 2022 2021 Cost of services $ 2,816 $ 3,058 Research and development 1,849 1,251 Selling and marketing 1 — General and administrative 1,137 593 Total depreciation and amortization expenses $ 5,803 $ 4,902

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related party expenses	Total related party costs are included within cost of services and related party expenses in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2022 2021 Cost of services $ 1,056 $ 278 Related party expenses 1,284 1,797 Total related party costs $ 2,340 $ 2,075

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2022
Debt Disclosure [Abstract]
Long-term debt maturities	As of March 31, 2022, long-term debt matures as follows (in thousands): 2022 (remainder of year) $ — 2023 875 2024 2,131 2025 2,174 2026 2,218 Thereafter 3,602 Total maturities of long-term debt 11,000 Less: current portion of long-term debt — Total long-term debt, net of current maturities $ 11,000

Leases (Tables)

Leases (Tables)	3 Months Ended
	Mar. 31, 2022
Leases [Abstract]
Lease, cost	The tables below present financial information associated with the Company’s leases. This information is only presented as of, and for the three months ended, March 31, 2022 because, the Company adopted the ASC 842 using a transition method that does not require application to periods prior to adoption (in thousands). Classification March 31, 2022 Assets Operating lease assets Operating lease right-of-use assets $ 38,417 Finance lease assets Property and Equipment, net 13,190 Total lease assets $ 51,607 Liabilities Current Operating Due to related parties $ 566 Short-term lease liabilities 1,892 Finance Due to related parties 304 Short-term lease liabilities 3,180 Non-current Operating Long-term lease liabilities 39,649 Finance Long-term lease liabilities 17,829 Total lease liabilities $ 63,420 Lease cost Three months ended March 31, 2022 Operating lease cost Operating lease cost $ 1,380 Short-term lease cost 169 Variable lease cost 127 Total operating lease cost $ 1,676 Finance lease cost Depreciation and amortization of leased assets $ 912 Interest on lease liabilities 552 Total finance lease cost $ 1,464 Total lease cost $ 3,140 Other information related to leases as of and the three months ended March 31, 2022 are as follows: March 31, 2022 Weighted-average remaining lease term (years) Operating leases 13.5 Finance leases 17.8 Weighted-average discount rate Operating leases 6.8% Finance leases 10.5% Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $1,236 Operating cash flows from finance leases $552 Financing cash flows from finance lease $862
Assets and liabilities, lessee	The tables below present financial information associated with the Company’s leases. This information is only presented as of, and for the three months ended, March 31, 2022 because, the Company adopted the ASC 842 using a transition method that does not require application to periods prior to adoption (in thousands). Classification March 31, 2022 Assets Operating lease assets Operating lease right-of-use assets $ 38,417 Finance lease assets Property and Equipment, net 13,190 Total lease assets $ 51,607 Liabilities Current Operating Due to related parties $ 566 Short-term lease liabilities 1,892 Finance Due to related parties 304 Short-term lease liabilities 3,180 Non-current Operating Long-term lease liabilities 39,649 Finance Long-term lease liabilities 17,829 Total lease liabilities $ 63,420 Lease cost Three months ended March 31, 2022 Operating lease cost Operating lease cost $ 1,380 Short-term lease cost 169 Variable lease cost 127 Total operating lease cost $ 1,676 Finance lease cost Depreciation and amortization of leased assets $ 912 Interest on lease liabilities 552 Total finance lease cost $ 1,464 Total lease cost $ 3,140
Finance lease, liability, fiscal year maturity	Future minimum lease payments under non-cancellable leases as of March 31, 2022 are as follows: Maturity of lease liabilities Operating leases Finance leases Total 2022 (remainder of the year) $ 3,862 $ 3,808 $ 7,670 2023 4,338 3,584 7,922 2024 4,440 2,763 7,203 2025 4,835 2,451 7,286 2026 4,949 2,003 6,952 Thereafter 51,920 49,884 101,804 Total $ 74,344 $ 64,493 $ 138,837 Less: imputed interest $ (32,237) $ (43,180) $ (75,417) Present value of lease liabilities $ 42,107 $ 21,313 $ 63,420
Lessee, operating lease, liability, maturity	Future minimum lease payments under non-cancellable leases as of March 31, 2022 are as follows: Maturity of lease liabilities Operating leases Finance leases Total 2022 (remainder of the year) $ 3,862 $ 3,808 $ 7,670 2023 4,338 3,584 7,922 2024 4,440 2,763 7,203 2025 4,835 2,451 7,286 2026 4,949 2,003 6,952 Thereafter 51,920 49,884 101,804 Total $ 74,344 $ 64,493 $ 138,837 Less: imputed interest $ (32,237) $ (43,180) $ (75,417) Present value of lease liabilities $ 42,107 $ 21,313 $ 63,420

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of stock option activity	The following summarizes the stock option activity, which reflects the conversion of the options granted under the 2017 Plan into awards with respect to the Company Class A common stock in connection with the consummation of the Business Combination (in thousands, except share and per share amounts): Stock Options Outstanding Weighted Average Exercise Price Balance at December 31, 2021 30,905,543 $ 1.24 Options granted 851,884 $ 3.37 Options exercised (2,108,502) $ 0.32 Options forfeited or canceled (759,629) $ 2.98 Balance at March 31, 2022 28,889,296 $ 1.33 Options exercisable at March 31, 2022 21,620,867 $ 0.54
Schedule of valuation assumptions	The fair value of the stock option awards for the period ended March 31, 2022, and March 31, 2021 were estimated using the Black-Scholes option pricing model with the following assumptions: Three Months ended March 31, 2022 2021 Expected volatility 65.20% - 67.60% 68.50%- 75.60% Expected term (in years) 5.48-6.06 0.50- 1.75 Risk-free interest rate 1.65%-1.70% 0.05%- 0.16% Dividend yield — — Fair value of Class A common stock $3.29-$3.45 $4.57- $12.51
Schedule of restricted stock units activity	The following table summarizes the activity related to the Company's time-based RSUs: Restricted Stock Units Outstanding Weighted Average Grant Date Fair Value Per Unit Balance at December 31, 2021 12,589,558 $7.64 Restricted Stock Units granted 762,190 $3.48 Restricted Stock Units vested (398,369) $7.63 Restricted Stock Units forfeited (830,620) $7.62 Balance at March 31, 2022 12,122,759 $7.38
Summary of stock-based compensation expense	Stock-based compensation expense for all awards granted and outstanding is included within the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended March 31, 2022 2021 Cost of services $ 1,381 $ 18,475 Research and development 4,341 38,187 Selling and marketing 2,825 18,688 General and administrative 9,012 89,612 Total stock-based compensation expense $ 17,559 $ 164,962

Net Loss per Share (Tables)

Net Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
Computation of basic and diluted net loss per share	Basic and diluted loss per share attributable to common stockholders was calculated as follows (amounts in thousands, except for share and per share amounts): Three months ended March 31, 2022 2021 Numerator: Net loss attributable to common stockholders $ (76,896) $ (191,775) Denominator: Denominator for basic and diluted earnings per share-weighted-average common shares 244,368,743 549,778 Basic and diluted loss per share $ (0.31) $ (348.82)
Potentially dilutive securities excluded from computation of diluted net loss per share	The following tables summarize the outstanding shares of potentially dilutive securities that were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been anti-dilutive: Three months ended March 31, 2022 2021 Outstanding options and RSUs to purchase Class A common stock 41,012,055 29,608,717 Outstanding warrants 21,994,972 — Outstanding earn-out shares 16,611,117 — Outstanding earn-out RSUs 2,410,459 — Redeemable convertible preferred stock (on an if-converted basis) — 171,535,214 Total 82,028,603 201,143,931

Organization and Description _2

Organization and Description of Business (Details)	3 Months Ended
	Mar. 31, 2022
Affiliated Entities
Organization and Description of Business [Line Items]
Conversion ratio (in shares)	123.8339

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ / shares in Units, $ in Thousands	Dec. 09, 2021d$ / sharesshares	Jul. 22, 2021shares	Feb. 09, 2021shares	Dec. 31, 2022USD ($)	Dec. 31, 2021USD ($)shares	Jun. 30, 2022USD ($)	Mar. 31, 2022USD ($)dsegment$ / sharesshares	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Jan. 01, 2022USD ($)	Sep. 04, 2021$ / shares
Property, Plant and Equipment [Line Items]
Number of reportable segments | segment							1
Proceeds from CARES act									$ 5,400
Employer payroll tax									3,800
Deferred employer payroll tax paid					$ 1,900
Accounts receivable, allowance for credit loss, writeoff							$ 500
Purchase of warrants (in shares) | shares		21,995,000			21,994,972
Public warrants (in shares) | shares					14,758,305
Expected term (in years)					5 years
Target share price of warrants or rights for redemption (in usd per share) | $ / shares							$ 18
Redemption price per warrant (in usd per warrant) | $ / shares							$ 0.01
Number of days for written notice of redemption | d							30
Minimum number of trading days | d							30
Restructuring charges							$ 2,700
Total stock-based compensation expense							17,559	$ 164,962
Operating lease assets					$ 0		38,417
Short-term lease liabilities							$ 42,107
Accounting Standards Update 2016-02
Property, Plant and Equipment [Line Items]
Operating lease assets										$ 39,200
Short-term lease liabilities										$ 42,200
Restricted Stock Units (RSUs)
Property, Plant and Equipment [Line Items]
Restricted Stock Units granted (in shares) | shares							762,190
Sema4 OpCo, Inc
Property, Plant and Equipment [Line Items]
Number of shares holder (in shares) | shares			35,000,000				19,021,576
Earn-out contingent liability							$ 3,400
Sema4 OpCo, Inc | Restricted Stock Units (RSUs)
Property, Plant and Equipment [Line Items]
Restricted Stock Units granted (in shares) | shares	2,700,000
Total stock-based compensation expense							$ 500
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche One
Property, Plant and Equipment [Line Items]
Public per share (in Dollars per share) | $ / shares	$ 13
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche Two
Property, Plant and Equipment [Line Items]
Minimum number of trading days | d	20
Consecutive trading day threshold | d	30
Public per share (in Dollars per share) | $ / shares	$ 15
Sema4 OpCo, Inc | Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche Three
Property, Plant and Equipment [Line Items]
Public per share (in Dollars per share) | $ / shares	$ 18
Class A Common Stock Equals or Exceeds, $18.00
Property, Plant and Equipment [Line Items]
Minimum threshold price of common stock specified to send notice of redemption to the warrant holders (in usd per share) | $ / shares							$ 18
Minimum number of trading days | d							20
Consecutive trading day threshold | d							30
Class A common stock
Property, Plant and Equipment [Line Items]
Purchase of aggregate private placement warrants | shares					1
Warrant exercise price (in dollars per share) | $ / shares											$ 11.50
Target share price of warrants or rights for redemption (in usd per share) | $ / shares							$ 10
Minimum number of trading days | d							20
Consecutive trading day threshold | d							30
Common stock threshold, number of trading days before notice of redemption | d							3
Redemption on warrant holders (in usd per share) | $ / shares							$ 18
Class A common stock | Sema4 OpCo, Inc
Property, Plant and Equipment [Line Items]
Number of shares holder (in shares) | shares		10,188
Class A common stock | Class A Common Stock Equals or Exceeds, $10.00
Property, Plant and Equipment [Line Items]
Target share price of warrants or rights for redemption (in usd per share) | $ / shares							10
Redemption price per warrant (in usd per warrant) | $ / shares							$ 0.10
Number of days for written notice of redemption | d							30
Public Warrants
Property, Plant and Equipment [Line Items]
Purchase of warrants (in shares) | shares		14,758,333
Private Placement Warrants
Property, Plant and Equipment [Line Items]
Purchase of warrants (in shares) | shares		7,236,667			7,236,667
Forecast
Property, Plant and Equipment [Line Items]
Deferred employer payroll tax paid				$ 1,900
Restructuring charges						$ 5,400
Government Assistance, CARES Act, Provider Relief Fund
Property, Plant and Equipment [Line Items]
Proceeds from CARES act								$ 5,600	2,600
Government Assistance, CARES Act, Employee Retention Credit
Property, Plant and Equipment [Line Items]
Proceeds from CARES act									$ 2,800

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Concentration Risk (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Customer Concentration Risk | Revenue | Payor A
Concentration Risk [Line Items]
Concentration risk, percentage	24.00%	14.00%
Customer Concentration Risk | Revenue | Payor C
Concentration Risk [Line Items]
Concentration risk, percentage		12.00%
Customer Concentration Risk | Revenue | Payor D
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	12.00%
Customer Concentration Risk | Accounts Receivable | Payor A
Concentration Risk [Line Items]
Concentration risk, percentage	26.00%		15.00%
Customer Concentration Risk | Accounts Receivable | Payor B
Concentration Risk [Line Items]
Concentration risk, percentage	19.00%		15.00%
Customer Concentration Risk | Accounts Receivable | Payor D
Concentration Risk [Line Items]
Concentration risk, percentage	11.00%
Supplier Concentration Risk | Purchases | Supplier A
Concentration Risk [Line Items]
Concentration risk, percentage	13.00%	11.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	[1]	Dec. 31, 2020	[1]
Accounting Policies [Abstract]
Cash and cash equivalents	$ 315,002	$ 400,569
Restricted cash	900	900
Total	$ 315,902	$ 401,469	$ 69,480		$ 118,960
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to certain current asset and liability accounts previously reported in the condensed balance sheets as of March 31, 2021. The adjustments are reflected accordingly as disclosed. T

Business Combination (Details)

Business Combination (Details) - Sema4 OpCo, Inc	Jul. 22, 2021USD ($)$ / sharesshares	Feb. 09, 2021USD ($)$ / sharesshares	Mar. 31, 2022shares	Dec. 31, 2021USD ($)
Business Acquisition [Line Items]
Business combination and net cash received	$ 510,000,000
Number of shares holder (in shares) | shares		35,000,000	19,021,576
Price per shares (USD per share) | $ / shares		$ 10
Share conversion ratio	0.01
Number of shares public offering		$ 350,000,000
Number of shares issued and outstanding (in shares) | shares	240,190,402
Prepaid expenses and other current assets
Business Acquisition [Line Items]
Transactions costs				$ 9,000,000
Merger Additional Capital
Business Acquisition [Line Items]
Transactions costs				$ 51,800,000
Class A Common Stock
Business Acquisition [Line Items]
Number of shares holder (in shares) | shares	10,188
Price per shares (USD per share) | $ / shares	$ 10
Number of shares public offering	$ 101,880
Class B Common Stock
Business Acquisition [Line Items]
Number of shares holder (in shares) | shares	178,336,298
Legacy Sema4 Shareholder payout	$ 230,665,220

Revenue Recognition - Disaggreg

Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Total	$ 53,941	$ 64,201	[1]
Diagnostic test revenue
Disaggregation of Revenue [Line Items]
Total	52,495	62,760	[1]
Patients with third-party insurance
Disaggregation of Revenue [Line Items]
Total	47,462	46,197
Institutional customers
Disaggregation of Revenue [Line Items]
Total	4,031	15,664
Self-pay patients
Disaggregation of Revenue [Line Items]
Total	1,002	899
Other revenue
Disaggregation of Revenue [Line Items]
Total	$ 1,446	$ 1,441	[1]
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to reclassify certain expenses between cost of services and operating expenses. The adjustments are reflected as disclosed.

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Revenue from Contract with Customer [Abstract]
Revenue recognized for reassessment of variable consideration	$ 3,600
Contract liabilities	66		$ 473
Revenue recognized included contract liability	500	$ 500
Deferred costs to fulfill contracts	1,500		$ 1,800
Deferred costs, current	$ 300	$ 300

Revenue Recognition - Remaining

Revenue Recognition - Remaining Performance Obligations (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-04-01 $ in Millions	Mar. 31, 2022USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue under existing collaboration service agreements	$ 10.3
Revenue under existing collaboration service agreements, period for recognition	3 years

Revenue Recognition - Contract

Revenue Recognition - Contract Assets and Contract Liabilities (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Contract Assets
Balance	$ 3,296
Contract asset additions	453
Balance	3,749
Contract Liabilities
Balance	3,769
Customer prepayments	350
Revenue recognized	(304)
Balance	$ 3,815

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term debt, net of current portion	$ 11,000	$ 11,000
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Long-term Debt, Fair Value	9,500
Level 3
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Earn-out contingent liability		$ 10,200
Change in fair value of warrant and contingent liabilities	$ 6,800

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Financial Liabilities:
Cash and cash equivalents	$ 315,002	$ 400,569
Level 3
Financial Liabilities:
Earn-out contingent liability		10,200
Fair Value, Recurring
Financial Assets:
Total financial assets	62,282	385,370
Financial Liabilities:
Earn-out contingent liability	3,432	10,244
Total financial liabilities	18,608	31,799
Fair Value, Recurring | Public Warrant
Financial Liabilities:
Warrant liability	10,183	14,463
Fair Value, Recurring | Private Warrant
Financial Liabilities:
Warrant liability	4,993	7,092
Fair Value, Recurring | Level 1
Financial Assets:
Total financial assets	62,282	385,370
Financial Liabilities:
Earn-out contingent liability	0	0
Total financial liabilities	10,183	14,463
Fair Value, Recurring | Level 1 | Public Warrant
Financial Liabilities:
Warrant liability	10,183	14,463
Fair Value, Recurring | Level 1 | Private Warrant
Financial Liabilities:
Warrant liability	0	0
Fair Value, Recurring | Level 2
Financial Assets:
Total financial assets	0	0
Financial Liabilities:
Earn-out contingent liability	0	0
Total financial liabilities	4,993	7,092
Fair Value, Recurring | Level 2 | Public Warrant
Financial Liabilities:
Warrant liability	0	0
Fair Value, Recurring | Level 2 | Private Warrant
Financial Liabilities:
Warrant liability	4,993	7,092
Fair Value, Recurring | Level 3
Financial Assets:
Total financial assets	0	0
Financial Liabilities:
Earn-out contingent liability	3,432	10,244
Total financial liabilities	3,432	10,244
Fair Value, Recurring | Level 3 | Public Warrant
Financial Liabilities:
Warrant liability	0	0
Fair Value, Recurring | Level 3 | Private Warrant
Financial Liabilities:
Warrant liability	0	0
Money market funds | Level 1
Financial Assets:
Money market funds	62,300
Money market funds | Fair Value, Recurring
Financial Assets:
Money market funds	62,282	385,370
Money market funds | Fair Value, Recurring | Level 1
Financial Assets:
Money market funds	62,282	385,370
Money market funds | Fair Value, Recurring | Level 2
Financial Assets:
Money market funds	0	0
Money market funds | Fair Value, Recurring | Level 3
Financial Assets:
Money market funds	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of utilized in determining valuation (Details)	Mar. 31, 2022$ / sharesyr	Dec. 31, 2021$ / sharesyr
Stock price
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input | $ / shares	3.07	4.46
Expected volatility
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.725	0.625
Expected term (in years)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input | yr	1.3	1.6
Risk-free interest rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent liability measurement input	0.0183	0.0058

Property and Equipment - Compon

Property and Equipment - Components (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		$ 114,625
Total property and equipment	$ 118,685
Less: accumulated depreciation and amortization		(51,906)
Less: accumulated depreciation and amortization	(57,709)
Property and equipment, net		62,719
Property and equipment, net	60,976
Equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	27,838	28,552
Finance lease, right-of-use asset, before accumulated amortization	21,384
Equipment under finance leases
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		21,384
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	21,915	21,905
Capitalized software
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	27,797	25,693
Building
Property, Plant and Equipment [Line Items]
Finance lease, right-of-use asset, before accumulated amortization	6,276
Building under finance lease
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross		6,276
Construction in-progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	2,709	940
Computer equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,536	6,634
Furniture, fixtures and other equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 3,230	$ 3,241

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 5,803	$ 4,902	[1]
Software amortization expense	$ 1,600	$ 1,200
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to certain current asset and liability accounts previously reported in the condensed balance sheets as of March 31, 2021. The adjustments are reflected accordingly as disclosed. T

Property and Equipment - Deprec

Property and Equipment - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	$ 5,803	$ 4,902	[1]
Cost of services
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	2,816	3,058
Research and development
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	1,849	1,251
Selling and marketing
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	1	0
General and administrative
Property, Plant and Equipment [Line Items]
Total depreciation and amortization expenses	$ 1,137	$ 593
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to certain current asset and liability accounts previously reported in the condensed balance sheets as of March 31, 2021. The adjustments are reflected accordingly as disclosed. T

Related Party Transactions - Na

Related Party Transactions - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021		Dec. 31, 2021
Related Party Transaction [Line Items]
Due to related parties	$ 3,237			$ 2,623
Cost of services	48,316	$ 68,524	[1]
Affiliated Entities
Related Party Transaction [Line Items]
Related party costs	2,340	2,075
Cost of services	1,056	278
Affiliated Entities | Cost of services
Related Party Transaction [Line Items]
Related party costs	1,056	278
Affiliated Entities | TSA Agreement
Related Party Transaction [Line Items]
Related party costs	0	1,400
Due to related parties	0			0
Affiliated Entities | Service Agreements
Related Party Transaction [Line Items]
Related party costs	1,900	$ 700
Due to related parties	2,500			2,600
Affiliated Entities | Purchase Of Diagnostic Testing Kits And Materials
Related Party Transaction [Line Items]
Purchases from related party	700
Payables	700			$ 100
Affiliated Entities | Purchase Of Diagnostic Testing Kits And Materials | Cost of services
Related Party Transaction [Line Items]
Purchases from related party	$ 400
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to reclassify certain expenses between cost of services and operating expenses. The adjustments are reflected as disclosed.

Related Party Transactions - Re

Related Party Transactions - Related Party Expenses (Details) - Affiliated Entities - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Related Party Transaction [Line Items]
Total related party costs	$ 2,340	$ 2,075
Cost of services
Related Party Transaction [Line Items]
Total related party costs	1,056	278
Related party expenses
Related Party Transaction [Line Items]
Total related party costs	$ 1,284	$ 1,797

Long-Term Debt - Loan and Secur

Long-Term Debt - Loan and Security Agreement (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Nov. 15, 2021USD ($)
Debt Instrument [Line Items]
Interest rate			4.00%
Other current liabilities	$ 23,384	$ 33,387
Long-term line of credit	$ 0
SVB Agreement
Debt Instrument [Line Items]
Existing issued and outstanding	65.00%
SVB Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Revolving credit facility			$ 125,000
Payments of debt issuance costs		$ 500
Debt instrument, debt issuance costs, each anniversary	$ 500
Other current liabilities	1,000
Line of credit facility borrowing capacity	$ 135,000
Number of borrowers	1.25
Trailing period for minimum revenue targets	6 months
Outstanding borrower	$ 50,000
SVB Agreement | Letter of Credit
Debt Instrument [Line Items]
Revolving credit facility			$ 20,000

Long-Term Debt - 2016 Funding C

Long-Term Debt - 2016 Funding Commitment (Details) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jun. 30, 2017	Mar. 31, 2022	Dec. 31, 2021	Nov. 15, 2021
Debt Instrument [Line Items]
Interest rate				4.00%
Outstanding loan balance		$ 11,000
DECD Loan Agreement
Debt Instrument [Line Items]
Total funding commitment	$ 15,500
Interest rate	2.00%
Administrative expenses over period	10 years
Outstanding loan balance		11,000	$ 11,000
Maximum loan forgiveness		12,300
Debt forgiven		$ 7,300

Long-Term Debt - 2020 Master Lo

Long-Term Debt - 2020 Master Loan Agreement (Details) $ in Millions	1 Months Ended
	Jul. 31, 2021USD ($)	Aug. 31, 2020USD ($)payment	Nov. 15, 2021
Debt Instrument [Line Items]
Interest rate			4.00%
Master Loan Agreement
Debt Instrument [Line Items]
Proceeds from loan		$ 6.3
Number of consecutive required payments | payment		60
Monthly required principal and interest payment		$ 0.1
Interest rate		4.75%
Repayment of long-term debt	$ 5.4
Debt instrument interest	$ 0.1

Long-Term Debt - 2020 Master Le

Long-Term Debt - 2020 Master Lease Agreement (Details) $ in Millions	1 Months Ended
	Jul. 31, 2021USD ($)	Dec. 31, 2020USD ($)payment	Nov. 15, 2021
Debt Instrument [Line Items]
Interest rate			4.00%
Master Lease Agreement
Debt Instrument [Line Items]
Proceeds from long-term debt		$ 3.6
Number of consecutive required payments | payment		60
Monthly required principal and interest payment		$ 0.1
Interest rate		3.54%
Letter of credit, deposit required, percent		105.00%
Repayment of long-term debt	$ 3.3
Debt instrument interest	$ 0.2

Long-Term Debt - Maturities (De

Long-Term Debt - Maturities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
2022 (remainder of year)	$ 0
2023	875
2024	2,131
2025	2,174
2026	2,218
Thereafter	3,602
Total maturities of long-term debt	11,000
Less: current portion of long-term debt	0
Total long-term debt, net of current maturities	$ 11,000	$ 11,000

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	1 Months Ended
	Apr. 30, 2019period	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Jan. 31, 2020	Apr. 01, 2019
Lessee, Lease, Description [Line Items]
Letter of credit | $		$ 0.9	$ 0.9
Capital lease, interest rate		13.10%
Building
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract				10 years	325 months
Lease cancellation period	196 months
Land to total value, percentage	25.00%
One Renewal Period | Building
Lessee, Lease, Description [Line Items]
Number of capital lease renewal terms	1
Lease term					10 years
Two Renewal Periods | Building
Lessee, Lease, Description [Line Items]
Number of capital lease renewal terms	2
Lease term					5 years

Leases - Lease, cost (Details)

Leases - Lease, cost (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Assets
Operating lease assets	$ 38,417	$ 0
Finance lease assets	13,190
Total lease assets	51,607
Non-current
Operating	39,649
Finance	17,829
Total liabilities	63,420
Due To Related Parties
Liabilities
Operating	566
Finance	304
Short-term Lease Liabilities
Liabilities
Operating	1,892
Finance	$ 3,180

Leases - Summary (Details)

Leases - Summary (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Operating lease cost
Operating lease cost	$ 1,380
Short-term lease cost	169
Variable lease cost	127
Total operating lease cost	1,676
Finance Lease Liability [Abstract]
Depreciation and amortization of leased assets	912
Interest on lease liabilities	552
Total finance lease cost	1,464
Total operating lease cost	$ 3,140

Leases - Schedule of future min

Leases - Schedule of future minimum rental payments for leases (Details) $ in Thousands	Mar. 31, 2022USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2022 (remainder of the year)	$ 3,862
2023	7,922
2023	4,338
2024	4,440
2025	4,835
2026	4,949
Thereafter	51,920
Total	74,344
Less: imputed interest	(32,237)
Short-term lease liabilities	42,107
Finance Lease Liability [Abstract]
2022 (remainder of the year)	3,808
2023	3,584
2024	2,763
2025	2,451
2026	2,003
Thereafter	49,884
Total	64,493
Less: imputed interest	(43,180)
Present value of lease liabilities	21,313
Total
2022 (remainder of the year)	7,670
2023	7,922
2024	7,203
2025	7,286
2026	6,952
Thereafter	101,804
Total	138,837
Less: imputed interest	(75,417)
Present value of lease liabilities	$ 63,420

Leases - Schedule of supplement

Leases - Schedule of supplemental information related to leases (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)
Weighted-average remaining lease term (years)
Operating leases	13 years 6 months
Finance leases	17 years 9 months 18 days
Weighted-Average Discount Rate [Abstract]
Operating leases	6.80%
Finance leases	10.50%
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	$ 1,236
Operating cash flows from finance leases	552
Finance lease principal payments	$ 862

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
Purchase commitment, remaining minimum amount committed	$ 19.4

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) $ / shares in Units, $ in Thousands	Jul. 22, 2021shares	Mar. 31, 2022USD ($)shares	Mar. 31, 2022USD ($)shares	Mar. 31, 2022USD ($)shares	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2022USD ($)employeeshares	Mar. 31, 2022USD ($)consultantshares	Dec. 31, 2021	Mar. 31, 2021USD ($)	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized stock-based compensation cost on the unvested stock options | $		$ 22,100	$ 22,100	$ 22,100	$ 22,100	$ 22,100	$ 22,100
Unvested company stock option | $		$ 2,700	2,700	$ 2,700	$ 2,700	$ 2,700	$ 2,700
Number of shares granted (in shares)						1	1
Total stock-based compensation expense | $			17,559						$ 164,962
Share-based payment arrangement, expense, reversal | $			$ 5,200
Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in us dollar)					$ 1.82
Restricted stock units forfeited (in us dollar)					0.29
Share-based Payment Arrangement, Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in us dollar)					1.39
Restricted stock units forfeited (in us dollar)					0.21
Share-based Payment Arrangement, Tranche Three
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted (in us dollar)					0.94
Restricted stock units forfeited (in us dollar)					$ 0.12
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average vesting period for compensation cost		1 year 6 months
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		4 years
Weighted-average vesting period for compensation cost		1 year 7 months 6 days
Stock conversion ratio		1	1	1	1	1	1
Unrecognized stock-based compensation cost on the unvested stock options | $		$ 60,200	$ 60,200	$ 60,200	$ 60,200	$ 60,200	$ 60,200
Restricted stock units granted (in us dollar)					$ 3.48
Restricted stock units forfeited (in us dollar)					$ 7.62
Restricted Stock Units (RSUs) | Share-based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting commencement date								12 months
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense | $			3,800
Outstanding vested value | $		$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of share issuance | shares		7,229,799	7,229,799	7,229,799	7,229,799	7,229,799	7,229,799
Number of shares equal to percent										1.00%
2017 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value re-measurement period for the liability awards									6 months
2017 Stock Incentive Plan | Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted | shares				0
Weighted average remaining contractual life (years), options exercisable		10 years
Vesting period		4 years
2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted | shares	0
Weighted average remaining contractual life (years), options exercisable	10 years
Vesting period	4 years
Number of share issuance | shares	32,734,983

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - Class A Common Stock	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Stock Options Outstanding
Beginning balance (in shares) | shares	30,905,543
Options granted (in shares) | shares	851,884
Options exercised (in shares) | shares	(2,108,502)
Options forfeited and cancelled (in shares) | shares	(759,629)
Ending balance (in shares) | shares	28,889,296
Options outstanding, exercisable at end of period (in shares) | shares	21,620,867
Weighted Average Exercise Price
Weighted-average exercise price (in dollars per share) | $ / shares	$ 1.24
Weighted average exercise price, options granted (in dollars per share) | $ / shares	3.37
Weighted average exercise price, options exercised (in dollars per share) | $ / shares	0.32
Weighted average exercise price, options forfeited and cancelled (in dollars per share) | $ / shares	2.98
Weighted-average exercise price (in dollars per share) | $ / shares	1.33
Weighted average exercise price, options exercisable (in dollars per share) | $ / shares	$ 0.54

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Assumptions (Details) - Options to purchase common stock - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility, minimum	65.20%	68.50%
Expected volatility, maximum	67.60%	75.60%
Risk-free interest rate minimum	1.65%	0.05%
Risk-free interest rate maximum	1.70%	0.16%
Dividend yield	0.00%	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	5 years 5 months 23 days	6 months
Fair value (in dollars per share)	$ 3.29	$ 4.57
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years 21 days	1 year 9 months
Fair value (in dollars per share)	$ 3.45	$ 12.51

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Restricted Stock Units (Details) - Restricted Stock Units (RSUs)	3 Months Ended
	Mar. 31, 2022$ / sharesshares
Restricted Stock Units Outstanding
Restricted Stock Units Outstanding (in shares)	12,589,558
Restricted Stock Units granted (in shares)	762,190
Restricted Stock Units vested (in shares)	(398,369)
Restricted Stock Units forfeited (in shares)	(830,620)
Restricted Stock Units Outstanding (in shares)	12,122,759
Weighted Average Exercise Price
Weighted Average Grant Date Fair Value Per Unit (in us dollar per share) | $ / shares	$ 7.64
Restricted stock units granted (in us dollar) | $ / shares	3.48
Restricted Stock Units vested (in us dollar) | $ / shares	7.63
Restricted stock units forfeited (in us dollar) | $ / shares	$ 7.62

Stock-Based Compensation - Su_3

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 17,559	$ 164,962
Cost of services
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	1,381	18,475
Research and development
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	4,341	38,187
Selling and marketing
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	2,825	18,688
General and administrative
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 9,012	$ 89,612

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Effective tax rate	0.00%

Net Loss per Share - Basic and

Net Loss per Share - Basic and Diluted (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2022USD ($)$ / sharesshares	Mar. 31, 2021USD ($)$ / sharesshares
Numerator:
Net loss attributable to common stockholders | $	$ (76,896)	$ (191,775)	[1],[2],[3]
Denominator:
Weighted average shares outstanding, basic (in shares) | shares	244,368,743	549,778
Weighted average shares outstanding, diluted (in shares) | shares	244,368,743	549,778
Basic loss per share (in dollars per share) | $ / shares	$ (0.31)	$ (348.82)
Diluted loss per share (in dollars per share) | $ / shares	$ (0.31)	$ (348.82)
Conversion ratio	123.8339
[1]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to certain current asset and liability accounts previously reported in the condensed balance sheets as of March 31, 2021. The adjustments are reflected accordingly as disclosed. T
[2]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made to reclassify certain expenses between cost of services and operating expenses. The adjustments are reflected as disclosed.
[3]	As previously disclosed in Note 2, “Summary of Significant Accounting Policies” to our consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021, certain adjustments were made which impacted previously reported net loss for the first quarter of 2021 and the adjusted net loss is reflected as disclosed.

Net Loss per Share - Potentiall

Net Loss per Share - Potentially Dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	82,028,603	201,143,931
Outstanding options and RSUs to purchase Class A common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	41,012,055	29,608,717
Outstanding warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	21,994,972	0
Outstanding earn-out shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	16,611,117	0
Outstanding earn-out RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	2,410,459	0
Redeemable convertible preferred stock (on an if-converted basis)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	0	171,535,214

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	Apr. 29, 2022	Jun. 30, 2022	Mar. 31, 2022
Subsequent Event [Line Items]
Restructuring charges			$ 2.7
Forecast
Subsequent Event [Line Items]
Restructuring charges		$ 5.4
Subsequent Event | Private Placement [Member] | Class A common stock
Subsequent Event [Line Items]
Sale of stock (in Shares)	50
Sale of stock shares price (in dollars per share)	$ 4
Private placement financing to sell	$ 200
GeneDx, LLC | Subsequent Event
Subsequent Event [Line Items]
Cash consideration	$ 150
Number of shares holder (in shares)	80
Earn-out contingent liability	$ 150
Earnout liability period	2 years
Maximum aggregate amount of cash consideration	$ 322
Maximum aggregate amount of cash consideration	$ 472